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Introduction 
Nous avons diagnostiqué et traité un patient atteint de nocardiose oculaire endogène. Grâce à la chirurgie 
vitréo-rétinienne, le diagnostique définitif a pu être établi avec un résultat oculaire fonctionnel excellent. La 
nocardiose oculaire endogène étant une maladie rare, l'image clinique oculaire et la prise en charge n'ont pas 
encore été décrites systématiquement. Nous avons analysé tous les cas rapportés dans la littérature mondiale 
(38 cas, publiés jusqu'en 2007) pour trouver des indices sur la physiopathologie, la présentation oculaire, sur 
la meilleure façon d'établir le diagnostique et sur l'efficacité du traitement antibiotique systémique. Enfin, 
nous avons établit des directives pour la prise en charge oculaire. 
La nocardiose (défini comme maladie systémique ou locale) est une maladie touchant surtout des patients 
immunosupprimés ou immunocompromis comme les patients transplantés, avec maladie auto-immune, 
atteints du virus HIV sans HAART ou des patients ayant subit un trauma, une opération avec inoculation du 
germe. Aux Etats-Unis environs 500-1000 nouveaux cas sont diagnostiqués par année avec 20% de 
dissémination dans des autres organes, le plus fréquemment dans le cerveau. Environs 0.6-1 % des patients 
(3-5 cas/année/US) auront un foyer dans l'œil, c'est-à-dire la nocardiose oculaire endogène. Nocarida est un 
Actinomycète, classé comme bactérie, avec une morphologie et un comportement proche aux champignons, 
avec un cycle de reproduction lente, se trouvant dans la poussière (ubiquitaire) et la matière végétale se 
décomposant. Elle est sensible aux sulfamides avec émergence de résistances. La mortalité est environs de 
25%. 
Résultats 
La moitié des patients présentait comme premier signe de la maladie systémique des problèmes oculaires, le 
plus souvent une baisse d'acuité visuelle progressive indolore. Un abcès choroïdien unilatéral unique dans la 
région maculaire associé ou non à un décollement rétinien séreux et/ou à une vitrite variable était la 
présentation dans 70% des cas. Nocardia dissémine au niveau des choriocapillaires, rarement, dans l'iris 
résultant dans un hypopyon isolé. Il y a deux modes de propagation locale: vers l'intérieur, par une nécrose 
de l'épithélium pigmentaire avec l'envahissement de la rétine et du corps vitré; vers l'extérieure, produisant 
une sclérite résultant dans une perforation du globe. Avant la séquestration au niveau du corps vitré, la 
réponse au traitement par antibiose voie générale est favorable: 75% des cas analysés. La rupture de la 
barrière hémato-oculaire externe (épithélium pigmentaire) peut être mis en évidence par la fluorescence 
angiographique : les images tardives montrent la diffusion de la fluorescéine dans le corps vitré. Si le corps 
vitré est atteint, au minimum des injections antibiotiques intravitréen (amikacin), mieux une vitréctomie sont 
indiqué pour diminuer la charge bactérienne et faciliter la pénétration des antibiotiques donnés par voie 
systémique. Signes d'une extériorisation d'un abcès choroïdien sont des douleurs intenses, l'exophthalmie et 
l'hypopyon associé. 
Soixante-deux pourcents des patients ont souffert d'une dissémination continue par retardement du 
diagnostique/traitement. La moitié des patients ont eu des abcès cérébraux avant, simultanément ou après 
présentation. Un quart des patients sont décédés suite de la nocardiose, 32% incluant la maladie de base 
(tumeur maligne hématologique) ou des autres infections opportunistiques (aspergillose). La morbidité 
oculaire est importante: un tiers des patients survivants ont retenu une acuité visuelle 0.5 ou mieux, un tiers 
une acuité visuelle égale ou inférieure à 0.1 et un tiers ont perdu l'œil par énucléation/éviscération(l). 
La suspicion clinique et la biopsie de la lésion pour un examen microbiologique direct et des cultures sont 
cruciales pour la prise en charge. Les risques facteurs sont sexe masculin ( 4 : 1 ), stéroïdes, 
immunosuppression pour transplantation ou maladie auto-immune et des tumeurs hématologiques malignes, 
plus rarement des accidents/ traumas graves. La ponction directe de la lésion assure les meilleures chances 
pour collectionner un spécimen contenant des bactéries: dans des petits abcès sous-rétiniens maculaires par 
ponction transvitréenne sous-rétinienne par aiguille fine décrit par le Prof. Augsburger (Référence 7) ou dans 
des lésions avancées par biopsie sous-rétinienne/rétinienne pendant une vitréctomie selon l'extension et la 
localisation de l'abcès. Le spécimen doit être préparé pour un examen direct ( 4 lames) et des cultures 
utilisant des plaques ordinaires sauf exceptions. La suspicion doit être communiquée au laboratoire et les 
cultures incubées de façon prolongée ( 4-6 semaines). Un bilan d'extension avec au minimum un CT scan 
thoracique et une IRM cérébrale sont indiqués. 
Le traitement de choix est un antibiotique du groupe des sulfamides à haute dose comme par exemple le co-
trimoxazole à double dose. Le choix, le nombre et le dosage du/des médicaments doivent être adapté selon 
résistance, extension de la maladie, médicaments autres et état de santé général du patient (foie, reins). Les 
figures 6a et 6b illustrent la prise en charge de patients selon diagnostique établit (Fig. 6b) ou non (Fig 6a). 
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Abstract. We present an illustrative case of endogenous ocular Nocardia (EON) infection in a man 
with Hodgkin disease treated by chemotherapy who underwent aggressive vitreoretinal surgery for 
diagnosis and treatment of a subretinal abscess. Visual acuity recovered from hand movements to 20/ 
25. We review the 38 reported cases of EON published between 1967 and 2007, describe the clinical 
presentation from a systemic and ocular point of view, examine which ocular procedures were 
successful in identifying the bacterium, and analyze ocular morbidity and the factors affecting 
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1. Introduction 
About 5-10% of all endophthalmitis is endogenous. 
Staphylococcus sp., Streptococcus sp., Escherichia coti, 53 
and Candida sp.94 account for most. In a recent 
single-center, 10-year, retrospective study,94 Nocardia 
sp. represented only 3% of endogenous endoph-
thalmitis. Nocardia was iclentified as the most 
frequent bacterial and Aspergillus as the most 
50 frequent fungal cause of a subretinal abscess. " As 
the result of its slow growth and choroiclal affinity, 
Nocardia endophthalmitis presents differently than 
other endogenous bacterial endophthalmitis. 
Nocardia, an actinomycetale, is a fungus-like, 
filamentous, slow-cycling, aerobic, Gram-positive 
b · 119 · l . bl . . A 'l actenum w1t 1 vana e sta1n1ng. s01 sapro-
phyte, it is found in dust and decaying vegetable 
matter. Immunocompromized men are particularly 
vulnerable to infection. The incidence of nocardio-
sis, defined as local or systemic infection by Nocardia, 
© 2011 by Elsevier Inc. 
Ail rights reserved. 
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in the United States was estimated in the 1980s to be 
between 500 and 1,000 cases per year. Eighty-five 
percent (85%) of patients have a serions pulmonary 
or systemic infection. 11 Spreading to distant sites 
occurs in about 20% of cases, the brain being the 
organ most affectecl (15%) .11 About 3-5% of those 
who have bacteremia will have a foct1s in the eye. 19 
Thus, 0.6-1 % of systemic nocardiosis is expected to 
develop endogenous ocular Nocardia (EON)-or 
about 3-10 cases/year in the United States. The 
clinical picture is highly variable. Since the in-
troduction of sulfonamides, mortality has greatly 
decreasecl, from 80% to 25%. Visual morbidity, 
however, remains substantial. Lakosha et al74 found 
Jhat in exo- and endogenous ocular Nocardia in-
fections, only 13% of eyes retained visual acuities of 
20/40 or more. 
We report a patient who presentecl with a sub-
retinal abscess as the initial manifestation of 
0039-6257 /$ - see front matter 
doi: 10.1016/j.survophthal.2011.03.003 
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disseminated nocardiosis. Aggressive vitreoretinal 
surgery established diagnosis and led to a good 
visual outcome. 
Because of the rarity of disease, the management 
of EON is not standardized. We analyzed all cases of 
EON published in Medline journals from 1967 to 
2007 in form of a retrospective case series. We 
describe clinicat presentation, methods of cliagnosis, 
treatment efficacy, and attempt to clevelop criteria 
for the management of EON. 
II. Case Report 
A 78-year-olcl man presented with a 2-week 
history of painless clecreased vision in his left eye. 
His medical history was significant for an acleno-
carcinoma of the prostate treated by a transurethral 
resection of the prostate 7 months previously and 
for a Hodgkin lymphoma stage IV of the sclerose-
nodular type, diagnosed 2 months before pre-
sentation. At that time, he had lost 15 kg, was 
pancytopenic, and had hepatosplenomegaly with 
portal hypertension. He improvecl after a short 
course of high-close steroids, followed by three 
recluced closes of chemotherapy AVBD (aclriamy-
cine, vinblastine, bleomycine, dacarbazine: the first 
and second cycles consisted of 50% of the total 
close of adriamycine and vinblastine and 66% of 
the total close of dacarbazine and bleomycine. 
During the thircl cycle all four agents were given at 
66% of the total dosage). Chemotherapy resultecl 
in a good clinical and biological response. 
Upon presentation 2 weeks after the third cycle 
of chemotherapy, the patient was on 2.5 mg/ clay 
preclnisone and weekly granulocyte colony-
stimulation factor injections. Visual acuity was 
20/20 in the right eye; he saw only hancl 
movements in the left eye. Intraocular pressure 
was 13 mm Hg in the right eye and 6 mm Hg in the 
left eye. Both eyes were pseudophakic. The left 
anterior segment and vitreous contained a few 
cells. Funcluscopic examination showed a yellow-
white subretinal mass temporal to the macula. The 
right eye was normal. 
The differential diagnosis incluclecl fungal en-
dophthalmitis, metastasis of prostate adenocarci-
noma, or Hodgkin infiltration. A vitreous tap was 
performed, but dicl not reveal any organisms 
(direct examination, culture, polymerase chain 
reaction [PCR] for bacteria and fungus) or 
malignant cells. Serologic work-up for ToxojJlasmo-
sis, Bartonella henselae, and HIV were negative. 
Three clays later, the patient's general health 
cleteriorated with fever (38.2C), neck stiffness, 
vertical gaze, and a left arm paresis, and he was 
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admittecl to neurology. Carcliovascular, pulmonary, 
abdominal, and laboratory exams were unchanged 
comparecl to post-chemotherapy stuclies: mild 
leucocytosis (12.6 G/L), hemoglobin at 115 g/L, 
decreased thrombocytes (114 G/L), and an ele-
vated CRP (20 mg/L) that increased the following 
clay to 65 mg/L. A brain computecl tomography 
( CT) scan showed a round lesion measuring 1 cm 
in diameter at the left superior colliculus, and 
magnetic resonance imaging (MRI) detected six 
aclditional lesions distributecl in both hemispheres 
with hypo-intense centers and annular enhance-
ment. A lumbar puncture yieldecl cloudy cerebro-
spinal fluicl (CSF) with 400 leucocytes/mm3 (41 % 
lymphocytes, 41 % neutrophiles, 13.5% monocytes/ 
macrophages, 3.5% plasmocytes, and 1 % eosino-
philes), no organism on smears, normal glucose, 
and increased total proteins (697 mg/L [normal, 
150-460 mg/L]). A chest CT scan showecl a con-
densation line not present on prior images in the 
left pulmonary apex compatible with infection or 
tumoral infiltration. A transthoracic echocardio-
gram was normal. A urinary tract infection was 
present. Intravenous ceftriaxone and clarithromycin 
were administrated, and prednisone was increased 
to 5 mg/ clay. 
Despite this treatment, the patient's condition 
dicl not improve. On ophthalmic follow-up 1 week 
after the vitreous tap visual acuity was still hand 
movements. The conjunctiva, anterior chamber, 
and vitreous now were severely inflamed. There 
was leucocoria. The subretinal abscess (Fig. 1) was 
associated with new superficial retinal hemor-
rhages. Confrontecl with a multifocal disease 
Fig. 1. Pre-operative picture of the left eye showing the 
peripheral temporal fundus with marked vitritis and a hazy 
yellow-white subretinal lesion with superficial hemor-
rhages. Visual acuity was hand movements. 
ENDOGENOUS OCULAR NOCARDIOSIS 
without a clear diagnosis the eye was considered 
the most accessible site for diagnostic biopsy. 
U nder local anesthesia a pars plana vitrectomy 
(PPV), a retinectomy of the peripheral temporal 
retina from the 2-5 o'clock position, and aspira-
tion of the subretinal abscess was done. This was 
followed by endolaser under perfluorocarbon 
liquids and instillation of silicone oil. The suspi-
cion of Nocardia was communicated to the micro-
biology laboratory. Examination of the subretinal 
material confirmed Gram-positive, branching fila-
ments consistent with Nocardia (Figure 2). Four 
hours after surgery the patient received high doses 
of intravenous trimethoprim-sulfamethaxozole 
(TM-SMX; 10 mg/kg/day and 50 mg/kg/day). 
After a latency of 10 days, Nocardia Jarcinica grew in 
cultures of the subretinal abscess and in one of the 
two samples of CSF. Blood cultures and all vitreous 
samples remained negative. N. farcinica was sensi-
tive to TM-SMX, meropenem, ciprofloxacin, and 
rifampicin and was resistant to erythromycin, 
clarithromycin, and clindamycin. 
The general condition of the patient improved. 
No postoperative ocular complication occurred. 
Best-corrected visual acuity improved to counting 
fingers after 1 week, then to Snellen 20/600 in 2 
weeks, and to 20/25 at 3.5 months. There was 
a choroidal scar in the region where the retinec-
tomy had been performed; the macula and periph-
eral retina remained attached under silicone oil 
(Fig. 3). 
Neurologically, the patient retained a memory 
deficit and a frontal lobe syndrome. Upon dis-
charge, oral TM-SMX (Bactrim forte 1000 mg three 
times a day) and prednisone 5 mg/ day were 
continued. No further chemotherapy was adminis-
tered, and the patient died 4 months later from 
progressive Hodgkin lymphoma complicated by 
Aspe1gillus pneumonia. At autopsy, Nocardia was 
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identified in the regressed abscess cavity of the 
mesencephalon, but not elsewhere. 
III. Ophthalmic Case Reports 
A. INCLUSION CRITERIA 
Thirty-eight previously published cases with en-
dogenous intraocular Noca:rdia were identified using 
the methods described in Section VII (Method of 
Literature Search). Most cases were published in 
E 1. l · h · G 96 i21 l . ng Is 1, w1t two n1 erman, ' anc one in 
P ioo Tl. d l' . ortuguese. urty-seven reports presente c m1-
cal data, 17 included histological findings, and one 
report consisted of ocular pathology87 with little 
clinical data. Clinical descriptions were all detailed 
l . l d . . f b . 149 exceptone, w uc 1 was a escnpt10n o a ra1n scan. 
The citation period covers 1967 to 2007. A further 
report136 published in 2008 was not included in the 
clinical analysis. Nevertheless, optical coherence 
tomography (OCT) descriptions were added. New 
therapy is discussed in section IV.B.14. 
B. EXCLUSION CRITERIA 
Case reports where another infection such as 
tuberculosis could be causing the ocular picture 
were excluded. One report of hematogenous 
spread of Nocardia to the orbit and a report of 
external ophthalmoplegia without intraocular in-
volvement were not included. Reports of Nocardia 
of the lacrimal ducts and exogenous Nocaidia 
after ocular surgery, trauma, or keratitis are not 
consiclerecl here. 
C. METHODS 
We analyzecl age, sex, underlying cliseases, mecli-
cations, systemic picture of nocarcliosis at presenta-
tion, its evolution, time to cliagnosis, number of 
ineffective treatments, effective treatments, systemic 
Fig. 2. A: Hematoxylin and eosin staining of a subretinal abscess composed essentially of necrotic tissue infiltrated by 
polymorphonuclear cells. Note retinal tissue at the top, stemming from the edge of the retinectomy. B: Gram stain of the 
subretinal abscess showing Gram-positive filamentous, branching bacteria characteristic of Nocardia species. 
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Fig. 3. A and B: Fundus photograph at 1 week after surgery, visual acuity was counting fingers with silicone oil 
tamponade. The haze is due to corneal edema. Note the area of the retinectomy temporally. C and D: Fundus photograph 
at 3.5 months after surgery showing a completely fiat macula under silicone oil tamponade and pigmented laser scars at 
the edge of the retinectomy. Best corrected visual acuity has increased to 20/25. 
recurrences, mortality; temporal relationship of 
ocular nocardiosis to systemic disease, ocular symp-
toms, ocular presentation, differential diagnosis, 
ocular evolution, diagnostic procedures on the eye 
or elsewhere, complications of ocular diagnostic 
procedures, outcome of eye after treatment, com-
plications of healed ocular Nocardia lesions and its 
treatment; initial and final visual acuities, enucle-
ation/ evisceration, and follow-up time. We consid-
ered fluorescein angiographie findings in respect to 
clinical picture and outcome of treatment and to 
the location of Nocardia identified histologically in 
treated and untreated eyes. Attention was given to 
symptoms and signs of severity of ocular disease. 
IV. Results of Literature Review of 
Endogenous Ocular N ocardiosis 
A. SYSTEMIC FEATURES AND MORTALITY OF 
NOCARDIOSIS IN PATIENTS WITH EON 
Thirty-seven clinical and one pathologic87 case 
were identified and analyzed. Overall, 47 eyes were 
affected by endogenous intraocular nocardiosis. 
Table 1 gives an overview of patients' age, sex, 
Nocardia species, underlying disease, steroids, im-
munosuppressives, and outcome. 
1. Species of Nocardia Reported in EON 
N. asteroides was isolated in 29 (91 % ) and 
N. farcinia in three (9%) patients. Species was not 
available in six reports. 
2. Age and Sex Distribution of Patients 
Patients from 8 to 83 years were affected, with an 
average age of 4 7 years and a median of 46 years. 
Thirty (79%) patients were male, 8 (21 % ) patients 
female, a male to female ratio of 4:1. 
3. Predisposing Risk Factors 
a. Diseases 
Almost half (17 /37; 46%) of the patients were 
organ transplant recipients (9 kidney, 5 bone 
marrow, 3 heart). Nocardiosis occurred within a year 
TABLE 1 t"l z 
Study Summaries l::l 0 
Nocardia Underlying Cause C1 t"l 
Au th or Year species Age Sex Condition Steroids Immunosuppressives of Death z 0 
Davidson33 1967 NA 46 m Obstructive jaundice 0 0 na c [F.l 
sec. cholelithiasis 0 
Meyer87 1970 NA 67 m Gunshot wound left 0 0 Se psis (N) Ci c 
chest, systemic ~ penicillin, 
cutaneous ulcer of z 
the wound, 0 
pneumonitis ~ not responding to 
antibiotics ...... 
Meyer87 1970 NA 56 0 m ns ns ns ns [F.l 
"0 1971 0 0 ...... Burpee- NA 20 m Booby trap explosion na [F.l 
in Vietnam 
Panijayanond99 1972 NA 50 m TPK 7-8 months Corticosteroids Azathioprine, na 
previous for arteriolar antilymphocytic 
nephrosclerosis, globulin 
duodenal ulcer and 
Jampol59 
surgery, infections 
1973 NA 40 m TPK 3 months ago for Corticosteroids Azathioprine Sepsis (N) 
Wegener's "high dose" 2-3 mg/kg/ day 
Sher123 
granulomatosis 
1977 NA 38 m Bruton's sex-linked Prednisone 50 mg/ day 0 Sepsis (N) 
hypogamma-
globulinaemia, 
various pulmonary 
infections since 
infancy, chronic 
Rogers111 
aggressive hepatitis 
1977 NSPP 77 f Lymphocytic lymphoma Prednisone Cyclophosphamide, Meningo-encephalitis 
Vincristine, radiation (N) 
Lissner75 1978 NA 60 m Undiagnosed Hodgkin Prednisone 0 Sepsis (N) 
disease, treatment for 60 mg/day 
sarcoidosis, h/ o 
severe pneumonia 
30 years ago 
( Conlinued on nexl page) 
TABLE 1 '-"' CIO 
Continued CIO 
Nocardia Underlying Cause 
Au th or Year species Age Sex Condition Steroids Immunosuppressives of Death [JJ 
"' -, 
Bullock19 
< 
1983 NSPP 15 m Paroxyxmal nocturnal Prednisone Methotrexate, na 0 
hemoglobinuria, 60 mg/day antilymphocytic '"O 
:::;" 
TPBM globulins & 
1.5 years ago, GVHD, ~ s 
obstructive jaundice 2.. 
proven drug (Jt 
cholestasis °' 
phenomenon on 'G; 
biopsy [JJ 
Ferry45 (1) 1988 NA 66 m Endarterectomy 6 weeks 0 0 na '"O 
before onset of ocular ~ 8 
symptoms cr 
Ferry15 (1) 1988 NA 49 f Systemic sclerosis with Prednisone 0 na 7 
diffuse interstitial 60 mg/day 0 
n 
pulmonary fibrosis 5' 
Mamalis78 1988 NA 44 m TPH 14 weeks previous Prednisone Cyclosporin 340 mg/ na cr (1) 
30 mg/day day, Azathioprine -, M 
100 mg/day 0 ,_... 
Price106 1989 NA 53 m 0, Fever, cough and 0 0 na 
,_... 
weight loss with 
Gregor52/Knouse 70 
beginning of disease 
1989 NA 46 m TPH 3-4 months ago, Prednisone Cyclosporin 1000 mg/ na 
rejection treated by 20 mg/day day, Azathioprine 
muromonab-CD3, 100 mg/day 
corticosteroids, DM 
Ishibashi57 1990 NA 27 m Systemic lupus Prednisone 0 na 
erythematosus since 60 mg/day 
age 14, nephrotic 
syndrome 2.5 months 
Phillips 101 
previous 
1992 NA 63 m Chronic lymphocytic Prednisone Fludarabine na 
leukemia, h/ o ~ [F.l 
several pneumonia Ci 
Niehues96 1996 NA 62 m TPK for terminal Methylprednisolone Cyclosporin Status epilepticus ::i:: r 
glomerulonephritis, 500 mg/day 200 mg/day secondary ~ 
3 years of dialysis, for acute rejection Nocardiosis ~ ~ 6 months after 5 days z 
...... 
transplantation, Ci 
two episodes of 0 z 
acute rejections ...... 
~ 
>-3 
~ 
Jolly62 1996 NA 40 f TPK 5 months ago Immunosuppressive x Necrotizing l!'l ns z 
granulomatous t) 
0 meningo- C1 
cerebromyelitis l!'l 
with ARDS (N) z 0 
Davitt31 1998 NA 80 f H/ o recurrent 0 0 Se psis c 
pneumonia, r;,i 0 DM, spinal cord ('.') 
ependymoma, c 
cholecystitis, ~ cholecystectomy 
Chaudhry21 1998 NSPP 44 m TPH 8 months Prednisone Cyclophosphamide na z 0 previous, idopathic ~ dilated 
Yap111 
cardiomyopathy 
...... 
1998 NA 49 f Systemic lupus Steroids in termi tten t na 0 
erythematosus, Cyclophosphamide r;,i ...... 
r;,i 
complicated by the past 6 years 
arterial hypertension, 
Suppiah127 
nephritis, psychosis 
1999 NA 45 m TPK 6 months previous Prednisolone Cyclosporin 275 mg/ na 
for severe 30 mg/ day and day, 
hypertension, 500 mg Azathioprine for 6 
rejections pulsed over 3 days months, 
discontinued about 1 
mon th 
previously, because 0 
white blood cells 
Tan12s 2000 NSPP 37 m TPK 3 months ago Prednisolone FK506 na 
idiopathie kidney 
Lakosha71 
failure, hepatitis C 
2000 NF 41 m TPBM 13 months Prednisone Tacrolismus Aspergillus pneumonia 
ago for CML, acute & 
chronic GVHD, DM 
Schriever121 2001 NF 40 m TPK 10 weeks ago for Corticosteroids Cyclosporin, na 
polycystic Azathioprine 
nephropathy, 
nephrectomy of the 
diseased kidney 
Korkmaz71 
1 week ago 
2001 NA 29 m Adamantiades-Behçet Fluocortolen 10 mg/ Azathioprine 150 mg/ na 
disease day day 
Ng95 2002 NA 69 m Rena! failure secondary Prednisone 0 na 
glomerulonephritis 
( Continued on next page) 
(,;:) 
CIJ 
'° 
TABLE 1 
"" '.D Continued 0 
Nocardia Underlying Cause 
Au th or Year species Age Sex Condition Steroids Immunosuppressives of Death [/l ~ 
'""' Azap9 / Bozbeyoglu15 
<
2002 NA 46 f TPK 16 years ago, Prednisolone Cyclosporin, na 0 
rejection Tacrolismus "O 
Kim69 :::;-2004 NA 8 m TPBM 18months ns Immunosuppressive x Recurrence ALL & 
for ALL, GVHD !:'... 
Moshfeghi93 2004 NSPP 19 m TPBM 15months 0 Cyclophosphamide, na 8 Q.. 
for AML, GVHD Daunorubicin, 
°' affecting skin, Etoposide, °' 
liver, intestines 6-thioguanine u:; 
Pelayes100 2004 NA 32 m Systemic Methylprednisolone Cyclophosphamide na [/l 
n lupus erythematosus 60 mg/day 1 g/month "O 
Yu148 2005 NA 41 f TPBM 7 months Prednisone Cyclosporin ARDS; Sepsis (N), ro 8 before for leukemia general seizure cr' 
Rafiei 109 n 2006 NA 62 m Idiopathie Steroids 0 na 7 
thrombocytopenic 0 
n 
purpura 0 
Heron54 2006 NA 83 m Gian t cell arteri tis Prednisone 0 Sepsis (N) cr' n 
25 mg/day '""' 
Dodds37 
Nl 
2006 NF 26 f Systemic lupus Prednisone Cyclophosphamide na 0 
'""""' 
erythematosus, '""""' 
chronic renal failure 
De Silva35 2006 NSPP 49 m Hepatits C, previously 0 0 na 
intravenous drug 
abuser, 
ZaatrehH9 
HN negative 
2006 NA 55 m TPK 5 years ago Prednisone Tacrolismus 10 mg/ day na 
10 mg/day 
0 = none; ALL = acute lymphocytic leukemia; AML = acute myeloid leukemia; ARDS = acute respiratory distress syndrome; CML = chronic myeloid leukemia; f = 
female; GVHD = graft versus host disease; h/ o = history of; m = male; N = Nocardia; NA = Nocardia asteroides; na = not applicable; NF = Nocardia Jarcinica; ns = not stated; 
NSPP = Nocardia not specified; TPH = heart transplant; TPBM = bone marrow transplant; TPK = kidney transplant. 
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. . 7 . 59 62 96 99 121 from transplantat10n m /9 ktdney, ' ' ' ' ' 
127· 128 3/3 heart,24·52·70·78 and 1/5 bone marrow 
recipients. 148 After 1 year, Nocardia affected 4/5 
bone marrow recipients 19•69•74·93 (all with graft-
versus-host disease) and two kiclney recipients, one 
16 years after transplantation with a previous epi-
socle of acute rejection9·15 and one after 5 years after 
transplantation without clescribecl previous rejection 
in a brief report. 149 Nine (24%) patients hacl an 
autoimmune clisease-systemic lupus erythematosus 
(4), Wegener granulomatosis (1), glomerulonephri-
tis (1), systemic sclerosis ( 1), Aclamantiacles-Behçet 
clisease ( 1), gian t cell arteritis ( 1). Seven ( 19 % ) 
patients hacl known hematological malignancy 
(Hodgkin lymphoma, lymphocytic lymphoma, acute 
and chronic lymphoid leukemia, acute and chronic 
myeloid leukemia, one not specifiecl). Four of those 
underwent bone marrow transplantation. Seven 
(19%) patients hacl liver disease-hepatitis or 
cholestasis of diverse causes ( cholelithiasis, chole-
. . d . cl 1) 1 l . 33-35 l . cyst1t1s, rug m ucec . n t iree patients t i1s 
was the major health issue. Two were not treatecl 
with antibiotics against Nocardia and recoverecl;35 
one recoverecl after cholecystectomy.33 Five (13%) 
hacl a recent history of surgery or trauma of an 
organ other than the eye: one caroticl endarterec-
tomy, one surgery for a cluoclenal ulcer after 
transplantation, one nephrectomy of cliseasecl kicl-
ney after transplantation (transplant surgeries were 
not counted in this group); traumas were a gunshot 
in the thorax and a booby trap explosion. One 
patient hacl idiopathie thrombocytopenic purpura, 
one hypogammaglobulinemia, and a chilcl hacl 
paroxysmal nocturnal hemoglobulinuria treated by 
bone marrow transplantation. One hacl no known 
underlying clisease. 106 Twenty-six (70%) hacl one 
preclisposing clisease, six ( 16%) hacl two, two 
hacl three, and one hacl four predisposing diseases. 
Only three patients hacl adclitional diabetes 
mellitus. 34,52,74 
b. lvledications 
Thirty-five reports specifiecl the immuno-
suppressive therapy when Nocardia became mani-
fest; two only statecl "on immunosuppressives. "69·95 
Figure 4 illustrates the clifferent regimens patients 
were on at presentation. The majority of patients 
were on steroicls (73%), either alone (19%) or in 
combination with one (35%) or two (19%) other 
immunosuppressive clrugs. Seven patients (19%) 
had no immunomodulatory therapy (group of 
trauma, surgery, liver disease, and healthy). Only 
one patient was on a combination of immunosup-
pressives ( cyclophosphamicle, daunorubicin, etopo-
sicle, 6-thioguanine) without corticosteroicls.93 
Steroids combined with two 
immunosuppressives; 7; 
19% 
Steroids combined with a • • : • : • : • : • : 
single immunosuppressive; 
13; 35% 
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Not specified; 2; 5% 
lmmunosuppressives alone; 
1;3% 
Fig. 4. Frequency of immunocompromizing treatments 
as reported in patients with endogenous ocular Nocardia 
infection. Steroids were used in over 70% of patients as 
part of the treatment regimens. A combination of 
immunosuppressives ( 4) was reported the least frequently; 
no report with two immunosuppressives without steroicls. 
Eleven reports specifiecl prednisone or equivalent 
dosages ranging from 10-75 mg/clay, (mean, 44 
mg/ clay; meclian, 50 mg/ clay). Immunomodulatory 
agents were of the following classes: anti-metabolites 
(9 times) (azathioprine [6], methotrexate [l], 
fluclarabine [l], 6-thioguanine [l]), T-cell inhibitors 
(8) (cyclosporin [4], tacrolismus [3], FK 506 [l]), 
alkylating agent (5) (cyclophosphamicle [5]), and 
diverse (antilymphocytic globulins [l], mitotic in-
hibitor [vincristine] [l], cytotoxic antibiotic [dau-
norubicin] [l], and topoisomerase inhibitor 
[ etoposicle] [l]). There were only few data about 
leucocytes and no report of CD4+ T-lymphocytes 
levels. 
4. Systemic Involvement in the Presence of EON 
About half of the reports inclicatecl a cluration 
of symptoms that variecl from 2 clays to 16 weeks, 
with an average of 3 and a median of 1.5 weeks 
before presentation. Forty-three percent (43%) of 
the patients presented with fever and a quarter 
(24%) with significant weight loss. The lung was 
affectecl in 57% at presentation and in 70% 
cluring the course of the clisease. Dissemination 
to the brain was cliagnosecl at presentation in 10 
(22%) cases and in a further 9 patients later. Two 
patients were asymptomatic,34·101 but hacl positive 
brain scans. In all, 51 % of the patients hacl 
cerebral complications. 
Eight (22%) patients hacl a cutaneous or sub-
cutaneous abscess at presentation, and 11 (30%) 
patients cleveloped this. Other organs affectecl were 
blood (4), joint (3), kidney (2), endocarcl (1), 
thyroicl ( 1), spleen ( 1), liver ( 1), prostate ( 1), 
testicle ( 1), and penis ( 1). One patient hacl a double 
infection with TrichojJhyton rubrum in his groin.9•15 
Continous clissemination after initial presentation 
occurrecl in 23 (62%) patients. 
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5, Disease Recurrence and Mortality of Patients 
with EON 
In 36 reports the range of follow-up was between 3 
weeks (patient's death) and 104 weeks, with a mean 
of 34 and a median of 26 weeks. Overall, eight 
(22%) patients suffered from recurrences: five had 
one,20,37,59,74,123 two had two, 34,99 and one had 
three. 127 Twenty-five patients (68%) survived nocar-
diosis and/ or the underlying disease. Ten (27%) 
patients died from their Nocardia.34·54·59·62·76·87·96·114· 
123
·
144 One patient had sulfonamide-intolerance 
requiring a change in antibiotics that was fatal. 59 
Bilateral EON did not confer a bad vital prognosis: 
seven of nine patients survived. One patient (3%) 
died due to progression of blood malignancy69 and 
one due to pulmonary aspergillosis. 74 
B. OPHTHALMIC FEATURES AND OCULAR 
MORBIDITY OF EON 
1. Laterality of Eye Involvement 
Twenty-nine (76%) had unilateral (12 OD, 17 OS) 
and nine had bilateral eye disease. 
2. Temporal Relationship of Ocular and 
Systemic Symptoms 
About half (20 patients, 53%) first sought meclical 
attention because of ocular symptoms. In 10 
patients9,15,37,54,69,74,76,87,121,127,148 EON clearly pre-
ceded systemic disease. In seven patients33·34·62·71 ·95 · 
qg 149 1 . l . h . 
· ' ocu ar symptoms were associatec w1t vanous 
systemic manifestations, and in three patients EON 
was isolated without any sign of systemic nocarcliosis 
(after endarterectomy,5 with hepatitis C,35 and with 
systemic sclerosis45 ). In the other 18 patients (47%), 
EON appearecl during the coursel9,2D,52,57,59,70,78,87, 
96 100 101 114 144 f · cl' · Of l · 
' ' ' ' o system1c nocar 10s1s. t 1ose, six 
patients24·93·106·109•123·128 presented with ocular 
lesions while being treatecl with systemic therapy. 
3. Ocular Symptoms 
Twenty-one reports specified the duration of 
ocular symptoms that variecl from 2 clays to 9 weeks 
(average, 2 weeks; median, 1 week). Taken from 34 
reports, 27 (79%) patients complained of reduced, 
blurred, or cloudy vision. More than one-third of 
patients ( 41 % ) had pain ( 10) or ocular discomfort 
(4). A minority had a history of redness (15%), 
floaters or a scotoma (11%), photophobia (3%), 
metamorphopsia (3%), or a "white pupil" (3%), 
which corresponded to a hypopyon. One eye of 
a patient who had bilateral disease was 
asymptomatic. 
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4. Visual Acuity at Presentation 
Visual acuity at presentation was reported for 35 
out of 4 7 eyes. Eighteen eyes ( 51 % ) had visual acuity 
equal or worse than 20/200. Two eyes were NLP-
one with advanced abscess formation, 114 the second 
with optic neuropathy and retinal detachment.45 
Fourteen (40%) eyes had VA equal or better than 
20/40, three eyes had less than 20/40, but better 
than 20/200. One patient had a history of posterior 
uveitis as part of Adamantiades-Behçet disease71 
with visual acuity of light perception. His visual 
acuity before nocardiosis was not reported. 
5. Ocular Findings 
Forty-six eyes were described clinically, and one 
eye was described as endophthalmitis with subreti-
nal abscess without other details. 149 
a. Confunctiva, cornea, sclera, orbit, exteriorization/ 
pe1foration 
Conjunctival injection was seen at presentation in 
11 eyes (24%) and in a total of 15 patients (33%) in 
the course of disease. Keratitis was not described, 
only corneal edema in an eye that had perfo-
rated 100and one with angle-closure glaucoma.34 One 
of the patients suffered from scleritis, 144 probably at 
the external sicle of a subretinal abscess. Proptosis 
was not a presenting sign, but four35·74·87·148 eyes 
(9%) developed it during the course of the disease. 
In three eyes proptosis was followed by exterioriza-
tion. 35·87·148 Two 71 ·100 additional eyes had exterior-
ization without mentioned proptosis but both with 
purulent clischarges. In all, in five eyes (10%) the 
abscess exteriorized. Table 2 gives an overview about 
the combination of ocular pain, proptosis and 
hypopyon in these eyes. N. asteroides was found in 
four eyes and N. farcinia in one eye. 
b. Anterior chamber; iris 
In 17 eyes (37%) anterior chamber inflammation 
was noted. In four eyes there was a hypopyon 
(9%).34·100·128·148 Three ofthose eyes, including the 
TABLE 2 
Critical Signs for Exteriorization/Pe1foration of the eyes 
DuringEON 
Au th or 
Meyer87 _ 
De Silva3~ 
Yu 148 
Korkmaz71 
Pelayes100 
Pain 
ns 
+ 
+ 
+ 
+ 
Pro ptosis 
+ 
+ 
+ 
- = absent; + = present; ns = not stated. 
Hypopyon 
ns 
+ 
+ 
+ 
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patient with Adamantiades-Behçet disease, had 
exteriorization. One recurrent hypopyon was the 
only ocular manifestation of nocardiosis. 34 Posterior 
synechiae20·109 were found in two eyes at presenta-
. d . . 1 121 1 l t10n, an one lns granu orna evo vec. 
c. Vitreous 
Fourteen eyes (30%) showed some degree of 
vitreous infiltration24•62•95at presentation, 11 with 
concomitant anterior chamber reaction. 20·45·57·71 · 
78,109, 114·123·144·148 Four of th ose eyes had severe 
vitritis. 20·62'114'148 Three more eyes20·33·99 developed 
vitritis during the course of disease-a total of 37%. 
d. Chorioretinitis, mbretinal abscesses 
In 35 eyes, the description of the fondus allowed 
us to gauge the number of lesions per eye. For the 
other eyes, there was either no view as the result of 
severe vitritis, a retinal detachment, or the hypo-
pyon was isolated. In some reports the fondus was 
not described in detail because the authors were not 
ophthalmologists. 
Two-thirds (24 eyes, 69%) had one single lesion 
described as a mass, an inflammatory mass, or 
chorioretinal exudate. Superficial or intraretinal 
hemorrhages were often associated. Eight eyes 
(23%) had three or more lesions. Three eyes (9%) 
had two lesions per eye. 
The macular region was affected in 24 (69%) 
eyes, 9, 15,20,24,33,45,52,54,57,59,70,74, 78,87,99, 121 including 7 
(20%) eyes with foveolar involvement. 19·45·69·93·95· 
101 106 Tl . . l 1 1 f'C l . 
· 1e reg10n outs1c e t 1e macu a was a 1ectec 111 
12 (343 ) eyes,20,24,37,45,62,76,87,93,123 and the region 
1 l . . 5(1401) 4587106109121 c ose to t 1e opt1c nerve 111 10 eyes. ' ' ' ' 
During the clinical course, there was an en-
largement of the original lesion in nine eyes 
393 
(383 ) .9.15,57,74,78,87,101,121,123 ln two patients87,123 
lesions developed in the fellow, initially unaffected 
eye. One eye of a heart transplant patient presented 
with cytomegalovirus ( CMV) retinitis shortly after the 
disappearance of Nocardia chorioretinal infiltrates. 24 
e. Serous retinal detachment 
Upon presentation, serous retinal detachment 
was either slight (8) or massive (3) in 1 (31 %) out of 
35 eyes. One eye's slight retinal detachment in-
creased. 33 Three other eyes developed de novo 
retinal detachment, one slight93 and two to-
tally.45·121 ln all, 14 eyes (40%) had retinal de-
tachments. One retinal detachment (funnel 
shaped) was complicated by secondary neovascular 
glaucoma. 121 
6. Fluorescein and Indocyanine Green 
Angiography of Acute and Healed Lesions 
Five authors54·76·78·93·101 reported EON-associated 
lesions on fluorescein angiography (FA). The 
earliest three reports looked at acute lesions 
(Table 3) and the later two at complications after 
recovery from EON. Phillips85 and Lissner76 ob-
served early blockage of choroidal background 
staining, which confirms the findings documented 
b B b 1 15 . . cl . . y oz eyog u us111g 111 ocyan111e-green ang10gra-
phy (ICG), with consecutive hypofluorescence at the 
lesion in late frames. The middle phase of FA is 
marked by leakage from the retinal vessels at the 
margin of the abscess and with their occlusion on 
the mass. 
Of most interest are the late phases of the FA. 
Mamalis, whose patient responded to systemic 
treatment, showed accumulation of dye in the 
subretinal space without diffusion into the 
TABLE 3 
Comparison of Fluorescein Angiography Findings in Three Reports 
Earl y Middle Late 
Au th or Phase Phase Phase 
Mamalis78 Not stated 
Phillips101 Blockage of choroidal 
background staining 
Lissner76 Blockage of choroidal 
filling 
Leakage of retinal 
vessels covering the 
mass 
Diffuse leakage of 
retinal vesse! 
Leakage at the margins 
of retinal vessels, 
occlusion over the 
mass 
Accumulation of dye in 
subretinal space 
Progressive leakage 
from the lesion 
Leakage of fluoresceine 
in to the vitreous 
Outcome 
Response to systemic 
treatment, scar 
Survived, no ocular 
response to systemic 
treatment 
Patient died 
Note that the eye of the patient ofMamalis responded to systemic treatment. There was no dye diffusion into the vitreous, 
as the outer blood-retinal barrier remained intact, whereas in the eye of Philips' patient fluorescein leaked in the la te phase 
into the vitreal cavity. In this case there was no response to systemic treatment. Lissner's patient did not receive systemic 
treatment as Nocardia was diagnosed at autopsy. A break of the outer ocular barrier was found in histology. 
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vitreous. 66 This is in contrast to the report by 
Phillips, where progressive leakage from the lesion 
into the vitreous was observed. This eye did not 
respond to systemic treatment. The same FA 
observation as in Phillips's patient was found in 
the eye of Lissner's patient, who died shortly after 
the FA. Ocular pathology found that 
a suppurative inflammatory process replaced 
the choroid and extended into the subretinal 
pigment epithelial space through gaps in the 
pigment epithelium to involve most of the 
overlying retina ... the necrosis was especially 
intense acljacent to Bruch's Membrane, where 
the choriocapillaris was totally obliterated .... 
Bruch's membrane appeared intact, but the 
area between Bruch's membrane and the 
disintegrating retinal pigment epithelium was 
filled with amorphous material. The overlying 
retina was necrotic but the internal limiting 
membrane was intact [page 390] .76 
This histological observation documents the 
disruption of the outer blood-retina barrier and 
with that the potential invasion of the vitreous cavity. 
It is only a matter of time until the vitreous is 
invaded if progression of disease cannot be stopped. 
The report of Moshfeghi77 documented the 
development of a subretinal neovascular membrane 
fed by a chorioretinal anastomosis 20 weeks after 
a subretinal abscess had healed. Rafiei92 docu-
mented a fibrovascular scar with tractional retinal 
detachment. FA showed areas of capillary non-
perfusion with secondary retinal neovascularization. 
7. Optical Coherence Tomography 
Vossmerbaeumer et al136 had a patient with 
a subretinal abscess with a serous retinal detach-
ment. FA showed late hyperfluorescence without 
leakage from the mass, ICG showed blocking. OCT 
images (Stratus OCT III) documented an "intact 
sensorineural retina over an adherent, homoge-
nously hyper-reflective nocardioma with massive 
subretinal fluid [page 382]." The lesion was stable 
under systemic treatment in contrast to concomitant 
brain abscesses. 
8. Ultrasound Findings of Acute Lesions 
Three authors reported the outcome of ultra-
sound exams of acute lesions: Yap et al reported on 
a patient who showed a 5-6 disk diameter large 
yellow flat choroidal lesion that appeared homoge-
nous of low-to-medium interna! reflectivity on 
ultrasound.11 7 Lakosha's case showed a kidney-
shaped (8 x 6 mm) lesion on ophthalmoscopy with 
a fluid level (posterior hypopyon) at its inferior 
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aspect and multiple hemorrhages in the overlying 
retina. On B-scan, there was an irregular elevation 
with a maximum thickness of 1.7 mm. 61 The 
superior region showed high reflectivity whereas 
the inferior aspect was of low reflectivity. A-scan 
confirmed the fluid nature of the inferior part, and 
it documented an area of increased reflectivity of 
the sclera (scleral inflammation) behind the lesion. 
Bozbeyoglu's patient showed a well-demarcated, 
white-yellow, elevated choroidal lesion with intra-
and subretinal hemorrhages above it. 15 On ultra-
sound, the mass appeared acoustically hollow and it 
had a thickness of 2.5 mm. 
9. Magnetic Resonance Imaging 
Yu et al 148 correlated MRI images of an eye with the 
histopathological findings after enucleation. Patho-
logically there was panophthalmitis with infiltration 
of the sclera, choroid, exudative retinal detachment, 
and vitreous hemorrhage. Tl- and T2-weighted 
images were helpful in demonstrating scleral thick-
ening, choroidal edema, retinal detachment, and an 
opaque vitreous. Diffusion-weighted axial images 
nicely demonstrated a sausage-like lesion in the 
subretinal space that corresponcled to the macro-
scopic form of the same abscess on a section of 
the eye. 
10. Differential Diagnosis Evoked by the Authors 
ln 20 reports, the evoked differential diagnoses 
were, in decreasing order: fungus (7 patients), 
metastasis ( 4), toxoplasmosis ( 4) and underlying 
disease [Adamantiades-Behçet disease, giant cell 
arteritis, leukemia, lymphoma] ( 4), tuberculosis 
(2), CMV (2), and amelanotic melanoma (1). 
11. Time to Diagnosis and Diagnostic Procedures 
In 38 reports the time to diagnosis was between half 
a week and 14 weeks, with a mean of 3.5 weeks. 
Bullock and Dodds alone macle a clinicat diagnosis of 
nocardiosis based on the eye lesions, patients' 
profiles, and systemic features that was subsequently 
confirmed by microbiology. In the other reports, the 
diagnosis was established only on microbiologie 
findings. In 19 (50%) patients the dia~nosis were 
based on ocular specimens, 33-35,37,45, 2,57,70,87,101, 
127
'
149 in 7 combinecl with other sites,9•15•71 •95•100•121 • 
123
•
148 in 16 ( 42%) from samples taken elsewhere 
tlian the eye, 19,20,24,59,62,69,74,78,87,93,96,99,l06,109,128,144 
and in 3 (8%) only at autopsy.54•76•114 
a. Specimens taken from elsewhere than the eye 
Specimen were taken from the lung (12) by 
broncheoalveolar lavage, fine-needle or open lung 
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biopsies, and one sputum; from skin abscesses (10 
biopsies); byblood cultures ( 4); and one eachfrom the 
brain, a submandibular mass, and the epidymis 
( orchiectomy78). 
b. Ocular specimens taken, successful versus unsuccessful 
procedures in identifying the pathogen 
Diagn.osis w~s es~ablished in. the rublished cases 
after evrscerat:Ion 111 one patient,8 and after di-
agnostic enucleation in six patients.33,45,i2i,i27,i48 
Five vitreal and one anterior chamber taps were 
performed: all were negative.34·35·37·95·i28 A repeated 
anterior chamber tap34 in the patient who had 
a hypopyon as the only ocular sign of EON was 
positive on smears and cultures. In three patients 
PPV was performed. Of those, two revealed Nocardia 
(1 smears and culture; 1 smears alone) 57·100 and 
one was negative. 148 
Transvitreal subretinal fine-needle aspiration bi-
opsy, as described by Augsburger,7·52·70 was positive in 
all four patients on whom it was performed.9·15·35·101 
Two p t' t 52·70·10 ' l l · · · · l l a ien s 1ac posit:Ive stammg anc growt 1 
in culture, one had prolonged negative cultures and 
a staining pattern compatible with Nocardia.35 The 
fourth had positive staining for N. asteroides, confirmed 
by growth of blood cultures.9•15 PPV combined with 
aspiration of the abscess was first performed in EON by 
Sher123 in 1977, and smears and cultures were positive. 
Two other reports followed, both with positive cultures 
(one from the vitreous cavity) .37·95 Overall, from 18 
diagnostic samples ( enucleations/ evisceration ex-
cluded), 6 (33%) specimens were negative in smears 
and culture. Of those samples, five were collected by 
vitreal taps and one by a PPV (without subretinal 
b . ) i48 E' l 10psy . it 1er smears and/ or cultures were posi-
tive in all four patients who had undergone transvitreal 
fine-needle biopsies, in all PPVs combined with 
subretinal aspiration biopsy (3), and two ofthree PPVs 
without aspiration biopsy of the lesion. Nocardia was 
also found on repeated anterior chamber tap ( 1), 
"drainage of subretinal abscess" 149 and collection of 
"leaking pus" of an eye with exteriorization.71 
c. Complications related to ocular diagnostic procedures 
Four (22%) eyes developed complications: four 
cataracts (vitreal tap, 128 and vitrectomy alone57), two 
combined with a retinal detachment (transvitreal 
fi 11 b' 9 15 . b' d . ne-neec e 10psy, ' vitrectomy corn me with 
aspiration of subretinal abscess95 ). 
12. Number of Ineffective Treatments before 
Diagnosis 
From 36 reports, 17 patients benefited from 
adequate treatment from the start; 11 patients had 
one and 8 patients had two to four ineffective 
395 
treatments before the definitive therapy was 
instituted. 
13. Efficacy of Trimethoprim-Sulphamethoxazole 
TM-SMX was an effective systemic treatment in 8 (22 % ) patien ts;20,52,67, 70, 71,74, 123, 127, 149 in 6 patients 
it was given in combination with other antibi-
otics.9•15·93·95·100·101·109 TM-SMX was not effective in 
five (13%) patients.37•57•62 ·106•128 Cephalosporines, 
amikacin, imipenem, ciproxine, and sulphonamide 
were used alone or in varions combinations. 
14. Responses of Eyes Exposed to Effective 
Systemic Antibiotic Treatment and Eyes that 
Failed to Respond 
Effective systemic antibiotic treatment was de-
fined as a systemic antibiotic that Nocardia is known 
to be sensitive to and a clinical response elsewhere-
for example, regression of brain abscess don1-
mented on MRI. Twenty-seven eyes (57 %) 
benefited from such a treatment. Of those, 20 eyes 
(74%) had a favorable response.9,15,19,20,24,52,57,69,70, 
74,78,93,95,106,109,123,12s,144 F' 20 1199100 101 Il ive eyes, ' ' · ' ' a 
infected with N. asteroùles, did not respond; in two 
eyes, the outcome was uncertain at the end of 
r Il 37,128 Tl . · l . LO ow-up. 1e pnnc1pa cause of failure was 
very advanced infection: one bilateral case20 had 
response of early lesions in one eye, but not of 
advanced lesions in the other eye under systemic 
sulfadiazine and chloramphenicol. A unilateral 
case
99 
was treated late in the evolution of disease 
with sulfisoxazole 4-6 g/ day, but after 11 days of 
treatment the eye was considered lost. A third 
patient101 was treated by intravenous (IV) TM-
SMX, but there was enlargement of the lesion over 
the course of disease with simultaneous regression 
of brain lesions. After repeated intravitreal injec-
tions of 400 µg amikacin and 2.25 mg cephazolin 
over 3 months, the lesion transformed into a scar. 
0 . 71 . l Al . ne patient w1t 1 c amant1ades-Behçet disease was 
treated for pneumonia with ceftazidine and clari-
thromycin until development of severe orbital pain. 
Thereafter, he received ceftriaxone and ciproflox-
acin for presumed endogenous endophthalmitis. 
After scleral perforation, the diagnosis of EON was 
established and he received TM-SMX. The eye was 
not enucleated but vision was completely lost. The 
!ast100 of the five patients had exteriorization of the 
disease at presentation and was treated by amikacin, 
meropenem, then TM-SMX and imipenem. Addi-
tional intravitreal injections of 200 µg amikacin and 
lmg vancomycin did not salvage the eye. Four of the 
five eyes had such advanced intraocular infection 
that systemic treatment was not therapeutic. 
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15. Systemic Recurrences by Sequestered 
Nocardia in the Eye 
In Burpee's patient both eyes were affected.20 The 
eye with the older lesion did not heal under systemic 
treatment. Indeed, the patient suffered from repeated 
systemic recurrences without identification. of a persis-
tent systemic fon1s. Recurrences subsrded after 
enucleation. This case illustrates that Nocardia inay 
sequester in the vitreous and be the cause of systemic 
recurrences and death unless the eye is treated. 
16. Evolution of Lesions after Initial Treatment, 
Secondary Complications, and their Treatment 
For 14 eyes, further evolution was reported. In 
eight eyes the abscess transformed into a chorior-
etinal scar.19,20,24,52,70,74,7S,101,144 Early lesions having 
"multiple small exudates regressed to form punched 
out chorioretinal scars surrounded by light pigmen-
tation resembling scars of presumed ocular histo-
plasmosis [page 669]. "20 Two eyes developed 
subretinal neovascularization with hemorrhage, 
one 19 after about 36 weeks and a second93 after 20 
weeks. The former patient had a chorioretinal scar 
measuring two disk diameters below the optic nerve 
with fingerlike projections to the fovea. Visual acuity 
was initially 20/30 in the acute phase of the abscess, 
dropped to 20/100, and stabilized after 2 years at 
20/60. The second eye had a parafoveal abscess that 
transformed into a macula pucker with a secondary 
subfoveal choroidal neovascular membrane fed by 
a chorioretinal anastomosis. The anastomosis was 
preoperatively photocoagulated, and the subretinal 
membrane excised, leaving a juxtafoveal area of 
atrophie retinal pigment epithelium and a parafo-
veal chorioretinal scar. After 8 months of follow-up, 
visual acuity was 20/20. 
A further patient initially showed a large sub-
retinal abscess with overlying retinal perivascular 
sheathing that transformed into an extensive fibro-
vascular scar after three months 109 associated with 
a tractional retinal detachment and cataract. A 
cataract also developed in another eye with retinal 
1 . . b' 9,15 detachment after fine-need e asprrat10n 10psy 
and in a third eye57 where the posterior segment was 
not described further. One eye had persistent 
macular edema after cataract extraction. 128 Two 
patients developed secondary glaucoma.34·109 One 
eye ended in phthisis bulbi95 requiring enucleation. 
17. Significance of Ocular Pain during EON 
Ten patients complained of pain at initial pre-
. Th t' t 9,15,52,70,123 benefitecl fr·om sentat10n. ree pa ren s 
quick diagnosis and systemic treatment with disap-
pearance of pain. One eye was already perforated. 100 
l . 35,71,148 c t cl The eye of three ot 1er patients periora e 
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thereafter (two retained the globe, one demonstated 
scleral perforation on pathology). Two of these 
patients had proptosis prior to the perforation. Two 
other painful eyes were enucleated, one because of 
a completely "destroyed" eye99 (scarce pathology) 
. d' . 45 99 H' 1 . 1 and one to obtam a ragnosrs. ' rsto og1ca 
examination of the latter demonstrated next to the 
subretinal abscesses a moderate inflammation of the 
iris and an unremarkable sclera. One patient's ocular 
pain was probably due to anterior chamber 
inflammation. 109 
Four patients complained of ocular discomfort: 
One patient suffered during the evolution of the 
disease from frank pain with proptosis that im-
proved with systemic treatment and recurred after 
withdrawal of treatment.74 An ultrasound examina-
tion demonstrated increased reflectivity behind the 
abscess in the sclera. The second patient received 
10% sulfacetamide drops before ophthalmologic 
examination that considerably improved his dis-
comfort despite a subretinal abscess in the back of 
his eye.76 Pathology showed no anterior segment 
inflammation and infiltration of the vitreous body 
adjacent to the abscess. The third patient hacl 
a painful, blind eye that was enucleated because of 
systemic recurrences thought to be metastatic from 
the eye.20 Pathologie findings demonstrated in-
filtration of the iris with chronic inflammatory cells, 
fi brin between the two leaves of the iris, the absence 
of scleral inflammation and sequestration of Nocar-
dia in the vitreous. The last patient had an isolated 
34 hypopyon. 
During the evolution of disease, two patients 
complained about new pain: one underwent di-
agnostic enucleation.33 The subretinal abscess 
showed infiltration up to the ciliary body. The other 
was enucleated for "enclophthalmitis"; histopatho-
. cl . . 'd cl 127 logrc escnpt10n was not provr e . 
Of great value is the report of Meyer87 who 
described an eye with a history of "fulminant" 
chorioretinitis: "Shortly, the eye became proptosed, 
and a mass developed over the lateral aspect of the 
globe. This mass appeared as though an abscess was 
forming and exudate was pouring from it [page 
538]." Microscopically, there was an intense in-
flammatory reaction of the sclera and Nocardia was 
identified within the sclera. 
Sixty-six percent of 14 painful eyes were reporte~ to 
have cells (mild to hypopyon [ 4]) in the antenor 
chamber. In the 18 other reports not describing pain 
o~· ocular discomfort, there were cells in the 1~~1teri~r 
chamber in 33% (mild to hypopyon [1]) · This 
hypopyon was observed in a patient who .lost 
consciousness shortly thereafter; ~he .. pat.1ent 
benefited from subconjunctival amikacm. ll1Ject10ns 
as an adjunct to systemic treatment. 
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There was no exteriorization/perforation or 
proptosis during evolution in the group without 
pain. Their pathology45•59•95'114•121 (5) did not show 
iris/ ciliary body or scleral inflammation. Pain in the 
eye in the acute phase of EON indicates iridocyclitis 
(5)2o,33,45,75,lo9 and/or scleritis with or without 
concomitant orbital infiltration. Perforation is im-
. (3 . l . 35 74,148 l 2 'tl t mment eyes wlt 1 proptos1s ' anc w1 1ou 
. . 71 100) pnor proptos1s ' . 
18. Pathology Findings Reported of Untreated 
Eyes, of Eyes with Treatment Failure and Eyes 
that Responded to Systemic Treatment 
An overview of the findings of 17 ocular pathology 
reports is given in Table 4. The specimens for 
pathology were taken at different time points during 
the disease: at autopsy (7 eyes), after diagnostic 
enucleation (5 eyes), aftersystemic treatmentwith no 
ocular response (3 eyes) and after goocl therapeutic 
response (2 eyes). One of the eyes that respondecl to 
treatment ended in phthisis, 95 the second came from 
a patient123 that succumbed after a recurrence of 
nocardiosis after a change of antibiotics. 
In the 12 eyes never exposed to systemic 
treatment, Nocardia was identified in the choroid, 
Bruch's membrane, subretinal space, and the retina 
in ail 12 eyes and in the vitreous in one eye. This is 
in contrast to three eyes exposed systemically to 
appropriate antibiotics and enucleated for treat-
ment failure. 20·99·100 In these eyes Nocardia was 
identified only in the vitreous cavity. At initiation 
of treatment, these eyes had advanced disease 
(visual acuity light perception, massive retinal de-
tachment;20 cloudy subretinal mass and delay of 
b k 99 . l . . 100) treatment y 2 wee s; eye wlt 1 extenonsaton . 
Two eyes treated with appropriate antibiotics were 
enucleated for the reasons mentioned previously. In 
both, no organisms were identified. Bo th had a short 
delay in diagnosis (1-2 weeks) and a subretinal 
abscess at presen tation. It is plausible that the vi treous 
was not invaded when treatment was initiated. 
19. Overall Evolution of Eyes, Visual Acuities of 
Survivors 
The overall outcome of ail affected eyes but 
one
149 is illustrated in Figure 5 (gray points at the y 
axis are those eyes whose visual acuities at pre-
sentation were not described). 
Analysis in respect to best or worst eye is 
documented in Table 5. 
Of 37 patients, 12 patients (32%) clied (14 eyes; 
nocardiosis and other reasons). Of the survivors, 10 
(31 %) eyes hacl visual acuties equal or better 20/40; 
one (3%) eye's visual acuity was between 20/40 and 
20/200; 11 (34%) eyes had visual acuities equal or 
397 
less than 20/200. Nine eyes were enucleated and 
one evisceratecl ( 31 % ) . 
V. Discussion 
A. COMPARISON OF OPHTHALMIC REPORTS 
WITH NOCARDIOSIS IN GENERAL 
The cases publishecl in the ophthalmic literature 
are similar (age distribution, strong male predomi-
nance, underlying diseases, corticosteroids as major 
risk factor, clinical picture of fever, weight Joss, skin 
lesions, and mortality) to those from the non-
1 1 . 1· 11 81 119 u cl d . opht 1a mie lterature. ' ' n errepresente 111 
the ophthalmic literature are patients with human 
immunodeficiency virus (HIV)/acquired immuno-
cleficiency syndrome (AIDS) (see subsequent discus-
sion) and patients with chronic pulmonary clisease.88 
Pulmonary disease complicated by nocardiosis is 
associatecl with a high one-week mortality (62%), 
although only 25% of deaths were attributed to 
nocarcliosis itself. Organ transplantation in our study 
and others88 is the most common unclerlying medical 
condition, followecl by HIV and chronic obstructive 
pulmonary disease. Autoimmune cliseases and hema-
tological malignancy treatecl with bone marrow 
transplants were slightly more frequent in EON. 
Hematological malignancies were twice as frequently 
associatecl with nocardiosis as solid tumors. 130 Graft-
versus-host-disease was suggested as a risk factor for 
nocardiosis in t:wo stuclies, 13'31 whereas one study 
found no difference. 133 In ophthalmic patients, 
almost 20% of patients had liver clisease. Hepatitis B 
and C or other hepatic clisease was found to be 
a preclisposing factor by at least two authors de-
'b' d' . . 1 1 ts 72·108 A sen ing nocar 10s1s u1 rena transp an . 
healthy person figures equally to another review88 
with 3%. Pulmonary infection was present in 70% of 
patients in other stuclies of nocardiosis88 as well as in 
the reviewecl ophthalmic cases. Radiologie findings 88 
cited in decreasing orcler were infiltration (60%), 
nodules (35%), cavitation (13%), and pleural effu-
sion (13%)-bilateral twice as often as unilateral. 
Thoracic computed tomography revealecl pathology 
in 12of15 patients. 
Brain involvement occurs in about half the cases 
of EON and is more frequent than in other series, 
such as Nocardia in transplant patients, but less when 
disseminating cases alone are analyzed (20% dis-
seminatecl, 15% to the brain).11 Mortality increases 
with brain involvement and with the number of 
, cerebral abscesses.79 
B. COMPARISON OF OUR CASE WITH THE 
OPHTHALMIC REPORTS 
Our patient presented many. of the typ~cal 
features of nocardiosis: male sex w1th hematolog1cal 
TABLE 4 '-"' 
<.D 
OO 
Pathology Findings of Posterior Segment Descriptions 
Vitreous with Vl i:: 
Circum- Culture Subretinal ..., < 
stance Au th or Positive Retina Space PE Break of BM Choroid Nocardia Found 0 
-a 
A Meyer87 destruction of neutrophils, disrupted, heavy infiltration BM, subretinal ;::;" ns & 
photoreceptor, nuclear debris, detached of inner space, e:... 
outer nuclear free pigment choriocapillaris in the retina s 2.. 
Meyer87 
layer granules (J( 
A 0 ns abscess ns 1 necrosis, abscess, BM, comea, cri 
hemorrhage sclera, in :§ 
the retina Vl 
A Jampol59 0 RD, necrosis, de bris disrupted 0 thickening, BM, choroid (1) ~ degeneration infiltration, (1) s hemorrhage, cr 
abscess (1) 7 A Sher123 0, necrosis, ns detached 1, necrosis BM, choroid, 0 
OD condensation hemorrhage interrupted retina, ("l 0 
strands (second eye, cr (1) 
antibiotic ..., 
Ni 
changed---+ death) 0 
Rogers114 
...... 
A 1 necrosis RD, abscess necrosis 1, granuloma with Subretinal abscess, ...... 
giant cells retina, choroid, 
vitreous 
A Lissner76 0, some infiltrated, abscess disrupted intact invasion of BM, choroid, 
infiltration necrotic choriocapillaris, subretinal PE 
by mononuclear abscess, necrosis space, ln 
necrotic 
retina, Nin 
the abscess 
Jolly62 
cavity 
A 0, infiltrated total RD granulom. ns ns ns subretinal 
abscess with abscess, PE 
histiocytes, 
rare tr:I 
multinucleated rn Ci 
giant cells ::i:: 
Davidson33 t"" DE brownish, destruction abscess, ns 1 infiltration abscess subretinal ~ liquefied hemorrhage space 
tr:I 
z 
..... 
Ci 
0 
z 
...... 
tr:I 
~ 
~ 
DE Ferry45 0, cloudy, total RD abscess disrupted, intact, with infiltration, BM, inner choroid, 
trj 
z 
hemorrhage, multiple Non it microabscess subretinal space ~ 0 
clumps of detachment inner ~ cellular necrotic choriocapillaris z material, 0 
fi brin, e 
infiltrated ln 
DE Ferry1s 0, proteinaceous total RD, abscess 1, focally infiltration, subretinal 0 ns n 
exudates, mild necrotic, destroyed choriocapillaris, abscess, PE e 
to moderate abscess abscess formation, 5 infiltration epitheloid and 
giant cells z 
Schriever121 0 DE 0 ns infiltrated ns ns ns epi-, intra-, ~ subretinal, choroidal 
Yu Ms ...... DE purulent RD abscess ns ns infiltrated choroid 0 
TF Burpee20 1 RD total infiltration vitreous ln ns ns ns ...... ln 
TF Panijay- l,large necrotizing ns ns ns ns vitreous 
anond99 hemorrhagic chorioretinitis 
abscess 
TF Pelayes100 ns ns ns ns ns fibrosis necrotic intraocular 
mass 
TS Sher123 OS 0, clear, status post gliosis, choroidal detached 1, destroyed fibrosis negative (treated 
PPV degeneration necrosis surgically 
Ng95 
and systemically) 
TS 0 extensive RD extensive ns ns serosanguinous no organisms found 
subretinal ciliochoroidal after 6 months 
proliferation effusion systemic 
treatment 
1 = positive finding; 0 = negative finding; A = autopsy; BM = Bruch's membrane; DE diagnostic enucleation; N Nocardia; ns not stated; PE pigment 
epithelium; RD = retinal detachment; TF = treatment failure; TS = treated successfully. 
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Out-corne 
Death r 
Enucleatlon .[ 
N~: 1·. • 
HM 
CF 
less than 20/200 · 
20/200 
20/160 
20/125 
20/100 
20/80 
20/63 
20/50 
Out-corne of ail eyes 
.. 
• • ... 
... 
20/40 +----r----+-----------
20/32 
20/25 
20/20 .,.._-+---~~-~~---+---~~-~ 
20120 20140 20/80 20/125 20/200 CF HM LP NLP 
Initial Visual Acuity 
Fig. 5. This chart summarizes the overall outcome and 
final visual acuities of ail eyes. For the gray points on the y 
axis under the terms enucleation and death, initial visual 
acuity was not clocumented. From ail patients one-third 
died, one-fourth lost one eye, and Jess than one-fifth 
retained visual acuities over 20/ 40. Or in other worcls, 
from the survivor's perspective, about a third of eyes 
retained good visual acuity of 20/ 40 or better, about 
a third had visual acuities 20/200 or Jess, and about a thircl 
of survivors were treated by enucleation. 
malignancy treatecl with high closes of steroicls and 
chemotherapy, and shortly thereafter appearance of 
a unilateral, single subretinal mass with an initially 
inconclusive vitreal tap. He subsequently clevelopecl 
encephalitis. Only an invasive vitreoretinal proce-
clure clarified the etiology and allowecl aclequate 
systemic antibiotic treatment. The improvement of 
visual acuity from HM to 20/25 was exceptional. 
C. HISTORY AND EPIDEMIOLOGY 
Edmond Nocarcl, a veterinarian, first isolated the 
pathogen from a bovine farcy (lymphadenitis) in 
TABLE 5 
Final Visua.l Acuity in Reported Patients 
Best Eye Worst Eye 
Final Visual 
Acuity (No. Patients) (%) (No. Patients) (%) 
2:20/40 7 28 5 20 
<20/40 1 4 0 0 
:::0201200 1 4 1 4 
CF 0 0 0 0 
HM 4 16 4 16 
LP 1 4 1 4 
NLP 3 12 4 16 
Enucleation 8 32 10 40 
CF = counting fingers; HM = hand movement; LP = 
light perception; NLP = no light perception. 
7 patients hacl bilateral disease. 
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Guadeloupe in 1888.97 Two years later, Eppinger 
reported the first human nocarclial infection.40 
Since then, a spectrum of disease ranging from 
benign skin infections to chronic actinomycotic 
mycetomas (by direct inoculation), and from 
self-limited bronchopulmonary infections (by in-
halation) to severe hematogenous disseminating 
disease, has been recognized. By means of DNA 
sequencing, the genus is quickly growing; at least 90 
species are iclentified as of December 2009.A 
Currently, 16-25 sf.ecies have been implicated in 
human disease. 17'2 '119 The most important are N. 
asteroides complex (N. asteroùles sensu stricto, N. 
farcinica, N. nova), N. brasiliensis, N. otitidiscavarium, 
and N. travelensis. The taxonomy is in constant 
evolution. 17 In 1988,27 only three Nocardia species 
had been identified: N. asteroides, N. brasiliensis, and 
one not stated. 138 
Wallace et al 138 describecl six clrug patterns (I-VI) 
to which 78 N. asteroides isolates were susceptible and 
suggested that more species are in the same group. 
Later, clrug patterns I, III, and V have been de-
terminecl to belong to N. abscessus, 145 N. nova, 131·137 
and N. jàrcinica, 139 respectively. N. asteroides clrug 
pattern type VI recently has been attributecl to the 
species of N. cyriacigea1gica by means of DNA-DNA 
hybridization. 28 Thus, the group of N. asteroides was 
until recently heterogeneous and because of this in 
the newer literature is called N. asteroùles complex; by 
conclusion, the publishecl cases of EON inclicating 
N. asteroides as infectious agent were not necessarily 
causecl by the same species. 
Various epiclemiological reports are published, 
but they are difficult to compare due to heteroge-
. ( . 1 l . 1 2 l 81 90 103 1 l . neity smg e iosp1ta s, ' ' ' severa iosp1-
tals, 33.43.44 one laboratory, 51 en tire 
. 49 64 105) R cl 1 l" cl countnes ' ' . eporte annua cases are lste 
in Table 6. Clusters of infections during construc-
tion work 116·120 or other situations (nosocomial 
outbreak) 42 are reportecl. Filice 46 reviewed and 
calculated the incidence of nocarcliosis from articles 
published between 1966 and 2004. He estimatecl the 
incidence of nocardiosis in a general population 
(USA, Australia, France) to be 0.35-0.4 cases per 105 
persons/year, a figure recently confirmed by a Span-
ish stucly. 88 In the HN-infected population he 
estimatecl 53 cases per 105 persons/year, and in 
bone marrow transplant recipients, 128 cases per 
105 persons/year. The frequency estimatecl in a HN 
p,opulation was 608 cases per 105 persons, and in 
a variety of transplantecl organs recipients at 1,122 
cases per 105 persons. 
Infection with HN is the main risk factor in some 
clinics. 21 ·63·103 Sorne Nocardia patients were newly 
cliscoverecl to be HN-infectecl. Low CD4+ T-
lymphocytes ( < 100-50 cells/mm3)21•102 are 
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TABLE 6 
Epidemiology Reports of Various Countries/Hospitals 
Au th or Geography 
Frumkin49 Israel 
Pintado102 Madrid, Spain 
Farina44 Nine city hospitals, Italy 
Georghiou51 One laboratory 
Matulionyte81 
Queensland, Australia 
Geneva, Switzerland 
KageyamaM Entire Japan 
Farina'13 Eleven cities in Italy 
Moiton90 Bordeau, France 
Dominguez38 Five local hospitals, 
Texas, USA 
Poonwan105 Entire Thailand 
Castro21 Miami, Florida, USA 
Ail species of Nocardia are inclucled. 
associated with nocardiosis in HIV. A study of 10 
HIV-positive patients found T lymphocytes at 62 ± 
21 cells/mm3 and a mean viral load of 86,500 
copies/mL (median 48,000 copies/mL; range 0-
397,000 copies /mL). ss Only one of th ose patients 
was on antiretroviral therapy. The overall incidence 
of nocardiosis among HIV-infected patients, how-
ever, is low in Spain (0.38%), 102 and the United 
States (0.19-0.3%), 68 but is more common in 
certain regions of Africa (4%). 63 Highly active anti-
retroviral therapy is expected to reduce the risk for 
nocardiosis through the recovery of cell-mediated 
immunity. Prophylactic TM-SMX to prevent Pneumo-
cystitis carinü infection does not seem to be pro-
tective against nocardiosis when prescribed three 
times weekly, 102 but may be more effective when 
given daily for 6 months post-transplantation4 or in 
an HIV-population.50 
Higher prevalence of nocardiosis in males is 
typical, except in systemic lupus erythematosus, 
where in one study 19 of 31 patients (61 %) were 
females. 91 Mortality, however, was higher in males 
with systemic lupus erythematosus and Nocardia. 
D. MICROBIOLOGICAL PROPERTIES OF 
NOCARDJA, COLLECTION OF A SPECIMEN, SMEARS 
AND CULTURES, THEIR SENSITIVITIES AND PCR 
STUDIES 
Nocardia are aerobic actinomycetes that belong to 
the family of Nocardiaceae. As in related high-GC 
content bac te rial families su ch as 1Wycobacteriaceae and 
Corynebacteriaceae the cell wall of nocardial species 
. b 1 . . 1 119 Tl f' conta1ns tu ercu osteranc anc. 1e genus o 
Nocardia encompasses strictly aerobic bacteria. Nocar-
dia are bacillary, branching bacteria of 1 ~lm diameter 
whose hyphae often fragment to coccobacillary 
Study periocl Nocardia spp No. Cases/year 
1965-1989 17 0.7 
1978-2001 34 0.7 
1982-1992 30 3 
1983-1988 36 6 
1989-2003 20 1.3 
1992-2001 303 33.3 
1993-1997 26 5.2 
1993-2003 11 1 
1994--1997 12 4 
1996-2003 96 12 
1999-2004 25 4.2 
forms. They are Gram-positive, but staining may be 
only weak and in a irregular manner14 (sensitivity 
65%, see subsequent discussion). They are partially 
acid-alcohol resistant to modified Ziehl-Neelsen 
staining and usually stain with modified acid-fast 
(Kinyoun) stain. In culture, Nocardiaare slow-cycling. 
They may take several days to weeks to grow to form 
white to yellow to orange colonies. 
For diagnosis, the presence of the bacteria is the 
l . . 14 . l . acceptec cntenon, except m sputum anc gastnc 
fluid, 14 because of possible presence of Nocardia in 
food. Multiple specimens must be taken as the 
bacteria is difficult to visualize because of the low 
number in tissues. Specimens may be taken by 
puncture or biopsy from virtually every organ. In the 
presence of confirmed pulmonary nocardiosis, di-
. b 1 . . cl' d14 agnost1c cere ra puncture 1s contra1n ICate 
because of a high risk of meningeal contamination, 
except in AIDS or severely immunocompromized 
patients who harbor sometimes more than one 
organism in one abscess. In the immunocompetent 
patient with brain abscesses smaller than a diameter 
of 2 cm, a trial of empüic treatment is thought to be 
sufficient. For abscesses larger than 2.5 cm diameter, 
craniotomy for the excision of the abscess has been 
recommended. 79 
To ensure appropriate staining and culture 
handling, the suspicion of nocardiosis should be 
communicated to the microbiology laboratory. Di-
rect stains are of major importance because of the 
_rapidity of diagnosis. Because of emerging resis-
tance, especially for N. farcinica, every effort to 
obtain cultures should be undertaken. Ordinary 
cultures such as blood agar, chocolate agar, and 
Sabouraud medium are suitable. Gentamicin in 
mold agar might inhibit the growth of certain 
species. If contamination by commensal bacteria 
402 Surv Ophthalmol 56 (5) September-October 2011 
occurs, which might inhibît Nocardia growth, a selec-
tive medium such as modified Thayer-Martin agar 
. l 'b' . b l 119 c 1 . w1t 1 ant1 10ucs may e usec. u tures are 111-
cubated at 32-37C in aerobiosis and eventually wîth 
5-10% of C02, which enables more rapid growth. 
Colonies appear after 2-3 days, but in samples 
containing very few bacteria, growth may take as 
long as 2-3 weeks. Twenty (20) days were reported as 
average time for culture to be processed, and 
presumptive identification was available after 4-7 
days. 12 Twenty percent (20%) of isolates were 
eventually considered nonsignificant in one micro-
biological laboratory.51 Factors important for de-
termination of clinical significance are the direct 
visualization on Gram staining, pure or predomi-
nant growth in culture and repeated isolation of 
Nocardia in serial specimens. Gram is the most 
sensitive staining technique, with sensitivity esti-
mated at 65%, and that of cultures, at 95%. 119 
Modified Ki.nyoun 14·119 stain is used to confirm the 
organism detected by Gram staining, which may be 
unreliable used alone, and distinguishes between 
Nocardia and bacteria Actinomyces and Streptomyces. 
A lot of effort has gone into developing molecular 
methods for Nocardia identification. PCR analysis for 
clinical specimens such as biopsies, pus, and bron-
choalveolar liquid are now available that assist with 
identification of species by means of sequencing 16S 
rRNA gene and/ or heat shock protein 65 
(hsp65). 16·30•113•142 Sequencing ofhsp65 was recently 
used to identify Nocardia on the species level in 
1 1. d . 1 . 146M externa eye c 1sease an one v1trea speomen. ost 
sensitive (300 bacteria in 2 µLor 90% sensitivity wîth 
negative predictive value at 80% and 100% specificity 
and positive predictive value) are techniques com-
bining real-time PCR with SYBR Green dye, an 
intercalating dye attaching to double stranded 
DNA,3 available in some laboratories. This technique 
can be completed in a few hours, compared to about 
2 weeks by conventional, phenotypic methods. 
Currently, direct staining, culture, and the anti-
biogram remain the pîllars of therapeutic manage-
ment, as there are variable sensitivities to antibiotics 
within the group of Nocardia. Four smears should be 
prepared for Gram, acid-fast, modified acid-fast, and 
fongus. Routine cultures including cultures for 
tuberculosis should be started. PCR methods en-
hance diagnosis, but antibiogram remain crucial to 
guide therapy. 
E. RISK FACTORS, STEROIDS, AND 
IMMUNOSUPPRESSIVES IN ANIMAL MODELS 
OF EON 
Nocardia has a low virulence and only becomes 
pathogenic when inhaled in high concentration 
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(before 1950, bringing in the hay), in immuno-
compromized patients, or by direct inoculation 
during surgery or trauma. Besicles pre-existing 
disease, corticosteroids are the main risk factor 
( 62 % in a recent study88). These 23 patients 
received a median dose of steroids of 25 mg (range, 
10-80 mg; with transplant recipients and patients 
with chronic pulmonary disease on the lower end 
and autoimmune diseases on the higher end) for 
a median duration of 3 months (range, 1-60 
months). Three of 7 organ transplant recipients 
recently had an acute rejection. In EON, 73% of 
patients were on steroids. Table 1 enlists the 
regimens patients were on. Corticosteroids have 
been shown both to decrease the mean lethal dose 
for N. asteroides sevenfold in mice89 and to increase 
the susceptibility for developing subretinal ab-
scesses 19 in rab bits. Figure 4 illustrates the immu-
nosuppressives patients were on at diagnosis of 
Nocardia. The percentages of treatment regimens 
are parallel to the surprising results found by 
Bullock in his animal models: 19 Rabbits pretreated 
with cyclophosphamide alone (here, one immuno-
suppressive) were less susceptible to ocular infection 
after inoculation of Nocardia in the animal's carotid 
than those pretreated with saline (here, on no 
immunosuppressive). The effect of cyclophospha-
mide found by Bullock was thought to be due to the 
suppression of B-cells and their influence on 
T-suppressor cells. 19 
F. DELAY IN DIAGNOSIS, DIFFERENTIAL 
DIAGNOSIS WITH RESPECT TO MICROBES 
POSSIBLY INVOLVED 
In the absence of clinical susp1oon, a delay in 
diagnosis ofup to 4 weeks îs common.81 This delay is 
clinically important, as there is proliferation of the 
germ and possible dissemination, which influences 
h 1. 126 Th . . 1 . h'b' t e morta 1ty rate. e mm1ma m 1 1tory con-
centration (MIC) increases with a bigger size of the 
inoculum, 5 makîng treatment more difficult in 
more advanced cases. 
The etiologic agents, the preferential hematoge-
nous spread to the choroid or retinal vessels, the 
rapidity of evolution, and the clinicat picture may 
help to distinguish among varions endogenous 
endophthalmitides. 
In the differential diagnosis, fungi were the most 
often mentioned. Candida, followed by Aspergillus, are 
tÏ1e most frequent causes of endogenous fungal 
125 cl h h 1 .. 86 . endophthalmitis. Candida en op t a m1t1s is 
easier to exclude as it presents with multiple cotton-
wool-like retinal infiltrates and with white string-
. h . no I 
of-pearl-like agglomerates m t e vltr~ous'. n 
contrast, Nocardia appears to have a pred1lecuon for 
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TABLE 7 
Calculated lntervals of lntravitreal Amihacin Injections 
Half-life Tl/2 (hours) Intravitreal Concentrations (~Lg/mL) Frequency of Ir~jections (days) 
After After After 
Eye Rab bit Hu man Injection 4*;Tl/2 5*;Tl/2 4*;Tl/2 5*;Tl/2 
Normal 25.5 43.4 100 6.25 3.125 7.2 9.0 
Aphakic 14.3 24.3 100 6.25 3.125 4.1 5.1 
Aphakic, vitrectomized 7.9 13.4 100 6.25 3.125 2.2 2.8 
Phakic & inflammation 15.5 26.4 100 6.25 3.125 4.4 5.5 
Aphakic & inflammation 7.4 12.6 100 6.25 3.125 2.1 2.6 
Aphakic, vitrecomized & 7.7 13.09 100 6.25 3.125 2.2 2.7 
inflammation 
Injections as 400 ~tg/mL in 4mL vitreous as a function of variable clearance of the human eye to main tain vitreal 
concentrations above MIC for amikacin. 
the inner choroid, 19•62•114 forming subretinal ab-
scesses and invading the vitreous late. Aspe1gillus 
forms subretinal abscesses 147 similar to Nocardia but, 
by its fulminant course, quickly invades the vitreous. 
Vitreous specimens are often positive for Aspeigil-
lus.147 Systemic risk factors for Aspergillus are similar 
to those for Nocardia. 110 
Endogenous endophthalmitis with Pseudallesche-
ria boydii, an opportunistic fungus 125 (with the 
asexual forms called Scedos~orium apiospermum58 
and Scedosporium prolificans13 ) affecting immuno-
compromized patients, was recently described. 
When affecting the posterior pole, these infections 
might initially look like EON, but with quicker 
invasion of the vitreous.58•132 Pseudallescheria boydii 
characteristically possesses enzymes dissolving the 
posterior lens capsule.83 Histologically, Pseudalle-
scheria boydii is indistinguishable from Aspe1gillus as 
its dichotomes hyphae branch at 45°. However, 
cultures look different, and there is resistance to 
conventional antifungals83 with limited sensibilities 
to voriconazole. 
Bacterial causes of subretinal abscesses include 
Klebsiella pneumonia, 53•55· 143' 147 Pseudomonas aem-
ginosa, 36· 140·141 Staphylococcus aureus, 26 Streptcoccus 
virùlans, 112 and Streptococcus pyogenes. 29 Klebsiella 
pneumonia subretinal abscess has a fulminant course, 
is associated with diabetes mellitus, and produces 
hepatic abscesses in 50% of the cases.53 It appears to 
be more frequent in East Asia. Pseudomonas aerugi-
nosa typically colonizes the lungs of patients with 
b l . . 141 . fib . 36 d ronc 11ectas1s or cyst1c rosis an can recur 
af 1 1 . 140 ter ung transp antat10n. 
Clinically, it is surprising that tuberculosis was 
mentioned only twice as an initial diagnosis. A single 
tubercle is, after disseminated choroiditis, the 
second most common clinical presentation of 
tuberculosis. 118 Incleed, the cell wall composition 
of Nocardia and Niycobacterium tuberculosis share 
a common constituent-tuberculosteraric acid. 
Furthermore, Niycobacterium t'!lberculosis resembles 
Nocardia in that both are slow-cycling organisms 
with a relative prolonged clinical history. In contrast, 
however, tuberculosis is not as ubiquitous, so that 
infection is not a particular concern, especially in 
relationship with immune suppression (except for 
TNF-et. blocker). 
Nocardiamay look like a choroidal tumor/ metastasis, 
by the relative absence of intraocular inflammation. 
Finally, two patients with known autoimmune dis-
eases (Adamantiades-Behçet Disease and giant cell 
artertitis) and two with hematological malignancies 
(leukemia and lymphoma) were thought to have 
recurrences of their initial disease. 
G. ROLE OF FLUORESCEIN ANGIOGRAPHY IN 
THE DIAGNOSIS AND TREATMENT, 
TRANSVITREAL SUBRETINAL FINE-NEEDLE 
BIOPSY VERSUS PARS PLANA VITRECTOMY 
Figure 6A illustrates an algorithm of how to 
manage a patient suspicions for EON. Transvitreal 
subretinal fine-needle aspiration biopsy, as de-
scribed by Augsburger6·7 was successful in yielding 
the diagnosis of nocardial subretinal abscess in ail 
cases in where it was used.9·52·101 It should be 
considered when the pigment epithelium appears 
intact-that is, when the fluorescein angiogram 
shows an early choroidal filling defect without late 
leakage from the mass into the vitreous. The 
technique of fine-needle aspiration consists of 
puncturing the subretinal abscess transvitreally via 
the pars plana using a 22-30-gauge sharp clisposable 
hollow-lumen needle, which is slightly bent at the 
,tip. The length of the needle depends on the 
location of the mass. The needle is connected via 
standard plastic tubing to a 10-mL aspiration syringe 
for the collection of the specimen. The technique is 
safe in trained bands. Major risk factors are retinal 
detachment and cataract. 
A Management of subretinal abscess suspicions for cndogenous ocular nocardiosis 
Systcmic involvement Funduscopy 
Skin 
Lung 
Brain 
other? 
Ü - subretinal abscess -
G) 
l 
Refer for biopsy 
FA: late leakage 
into vitreous? 
OG 
/ ~ 
Transvitrcal subrctinal 
fine needlc aspiration 
biopsy 
Pars plana vitrectomy 
vitreal & subretinal biopsies 
Peripheral, large les ions or specific 
circumstances: + vitreal laps + intravitreal antibiotics Primary retinectomy, endolaser 
photocoagulation, silicon oil/gas tamponade 
ln collaboration \~it~ infectious. disease spedalist and treating doctors, after diagnosis the patient receive high 
dose system1c ant1b10t1cs, tapenng of system1c and local steroids. Give topical non-steroidal anti-inflammatory 
drops.Thereafter observe and proceed following Fig. 6b 
8 Management of subretinal abscess under systemic treatment (efficient elsewhere) 
Funduscopy 
subretinal abscess 
•A: late leakage 
into vitreous? 
OCT: break PE? 
OG 
/ ~ 
Observe 
OR 
Additional repeated 
subconjunctival antibiotics 
Retinal neovessels after massive 
occlusion of retinal capillaries 
over the abscess 
RepeatFA 
for complications: 
Additional pars plana vitrectomy 
( vitreal & subretinal biopsies to confirm diagnosis) 
± retinectomy, endolaser photocoagulation, silicon 
oil/gas tamponade for 
peripheral, large Jesions or in specific circumstances 
OR 
Additional repeated intravitreal antibiotics 
macular and small peripheral lesions 
Chorioretinal neovascular membranes 
after a break in the pigment epithelium 
Fig. 6. A: About half of the patients first present to the ophthalmologist. The flowchart illustrates the algorithm on how to 
manage a suspected endogenous ocular Nocardia infection. The initial question is if the abscess is isolated in the eye or 
other organs are affected: The skin is involvecl in about half of the patients and is easy accessible for a diagnostic biopsy. If 
the abscess is isolated in the eye or biopsy of other organs is not indicated or too risky, diagnostic biopsy should be clone in 
the eye. A fluorescein angiography helps to choose the appropriate technique in fonction of the layer affected by the 
infection: penetration into the vitreous is likely if there is late leakage of FA from the mass into the vitreous traducing 
a disintegrated pigment epithelium. If positive, a diagnostic and therapeutic PPV together with subretinal biopsies should 
be performed at first. If negative, the infection is at an initial stage, limited to the subretinal space: A transvitreal fine 
needle aspiration of the chorioretinal lesion and systemic therapy is the preferred option. B: The other half of the patients 
have a non-ocular infection diagnosed and treated elsewhere. The ophthalmologist is asked to evaluate the lesion in the 
eye. The question is if the abscess is likely to respond to the systemic treatment alone. Again, a fluorescein angiogram 
should be perfonned in order to evaluate penetration of Nocardia through the outer ocular barrier, especially into the 
vitreous. If leakage from the mass into the vitreous is present on late frames, at least injection of intravitreal antibiotics or 
a pars plana vitrectomy should be performed. On long tenn the patient should be examined periodically in order to catch 
complications after scarring such as subretinal neovascular membranes or retinal neovessels .. FA = fluorescein 
angiography; OCT = optical coherence tomography; PE = pigment epithelium; PPV = pars plana V1trectomy. 
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In advanced cases, where Nocardia has invaded the 
vitreous, the ocular prognosis appears to be bleak 
even with adequate systemic treatment. Such treat-
ment may eliminate Nocardia at the level of the 
choroid, Bruch 's membrane, and pigment epithe-
lium, but Nocardia persists in the vitreal cavity. 
Vitritis is nota reliable sign for vitreous involvement, 
but late leakage of fluorescein from the mass into 
the vitreous indicates necrosis and a break of the 
outer blood-ocular barrier with potential vitreal 
invasion. A PPV, combined with a subretinal biopsy, 
is probably the best diagnostic and most efficient 
therapeutic choice in such eyes. Additional retinec-
tomy with eradication of the subretinal abscess, as 
performed in our patient, is justified in selected 
cases, depending on the location and extent of the 
abscess, and on the posterior vitreous if detached or 
not over the abscess. 
1. APPROPRIATE SYSTEMIC ANTIBIOTICS 
1. lntraocular Drug Levels Attainable with 
Systemic or Regional Administration of 
Antibiotics 
A comprehensive summary for systemic therapy 
and a table of minimal inhibitory concentrations 
(MIC) values, ranges, and breakpoints was pub-
lished previously.82 Ideally, minimal bactericidal 
concentrations (MBC) should be about tenfolcl 
higher to be sure of bactericidal effect85 in the 
eye. Instead, often MIC are measured, and MBC are 
not known. Data on ocular pharmacokinetics are 
limited. Nevertheless, we try to summarize what is 
known. Close follow-up will guide therapy. 
Nocardia species are classified by their antimicro-
bial susceptibility patterns. 138 Most Nocardia species 
are susceptible in vitro to sulfonamides (with or 
without trimethoprim), considered as the treatment 
of choice for nocardiosis. TM-SMX is the preferred 
formula because of the general familiarity with the 
drug. In disseminating disease combined antibiotic 
treatment should be considered. 
In vitro, N. asteroides complex (type VI drug 
susceptibility pattern) 17 consists of sensitivity to 
ceftriaxone, amikacin, linezolid, and imipenem 
and resistance to ampicillin, amoxicillin-clavulanic 
acid, clarithromycin, and ciprofloxacin. N. Jarcinica 
(type V drug susceptibility pattern), however, is 
sensitive to ciprofloxacin, linezolid, and imipenem; 
resistant to aminoglycosides except amikacin; and 
resistant to ampicillin, broad-spectrum cephalospo-
rins, and clarithromycin. Both are sensitive to 
amikacin, linezolid, and imipenem; in addition, 
N. asteroides complex is susceptible to ceftriaxone, N. 
farcinica to ciprofloxacin. 
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For the treatment of cerebral nocardiosis, the 
addition of at least a cephalosporin ( cefuroxime or 
ceftriaxone) or ciprofloxacin to TM-SMX has been 
proposed.82 Another group states that "most clini-
cians recommend a three-drug regimen consisting 
of TM-SMX, amikacin, and either ceftriaxone or 
imipenem for patients with serious disease, CNS 
disease, and/ or disseminated disease [page 271] ." 17 
It may sometimes be necessary to use other 
antibiotics ( e.g., macrolides, tetracycline), but these 
drugs are not discussed here. 
Sulfonamides and TM-SMX are bacteriostatic by 
interference with microbial folie acid and purine/ 
DNA synthesis. Recommended treatment for cere-
bral nocardiosis in adults consists of high-dose 
intravenous TM (15-20 mg/kg/day) and SMX 
(75-100 mg/kg/ day) for about 6 weeks 79 or TM-
SMX 160 mg/800 mg IV every 6 hours or two pills 
double-strength twice daily82 followed by 1 year of 
oral antibiotics in immunocompromized patients. 
Patients infected by HIV require longterm mainte-
nance therapy. Sulfonamide and TM-SMX both have 
good CSF penetration. Sulfonamides are metabo-
lized to an inactive component in the liver, 
metabolized, and free drug is excreted by the 
kidneys. Dosage must be adapted in renal insuffi-
ciency when clearance is below 30 mL/min. Adverse 
reactions are acute hemolytic anemia, leukopenia, 
thrombocytopenia, and agranulocytosis. TM-SMX 
should not be given in patients with known de-
ficiency in folie acid, glucose-6-phosphate dehydro-
genase, or known sulfa-allergy. A much higher 
frequency in adverse reactions-skin rashes, cytope-
nia, and hepatotoxicity-occurs in patients affected 
by AlDS. Concomitant use of cyclosporin in kidney 
transplant enhances its nephrotoxicity. Severe cyto-
penia may occur with simultaneous use of metho-
trexate and TM-SMX. 
Recently, MIC90 was determined at 1/19 µg/mL 
(TM/SMX) and MIC ranges :50.5/9.5 ~tg/mL to 
> 2/38 µg/mL of 51 isolates of Nocardia spp. 23 with 
four isolates resistant, two belonging to N. Jarcinica 
and two to N. cyriacigeorgica (formerly N. asteroides 
type VI drug susceptibility pattern). 
There are no ocular studies of TM-SMX in double 
dosages recommended for nocardiosis. Aqueous 
humor concentrations were measured for usual 
dosages of TM-SMX. There was 0.25 µg/mL 104 of 
TM after 1 day, 1.51 ~tg/ mL m after 3 days, and 
1.37 ~tg/mL117 of TM after 7 days in the anterior 
chamber. SMX was measured at 17.3µg/mL104 after 
n1 115 ~ I L117 1day,13.5 µg/mL after 3 days, anc .b µg m 
of free SMX after 7 days in the anterior chamber. In 
one study, 111 in 2 of 37 samples, liquefied vitreous was 
present; one sample after a single administration of 
double strength TM-SMX and one sample after 
406 Surv Ophthalmol 56 (5) September-October 2011 
steacly-state equilibrium after three clays treatment. 
Both samples where in harmony with the results 
of aqueous hum01~ so that it was concluclecl that 
the concentration of TM-SMX at least in the 
liquefiecl vitreous are similar to that in aqueous 
humor. 111 
Intraocular penetration of TM-SMX in rabbit eyes 
cleliverecl subconjuntivally, retrobulbarly, or single--
dose intramuscularly (0.25 mg/0.1 mL; 2.5 mg/mL; 
2.5 mg/kg TM-SMX, respectively) was concluctecl in 
1989 for the treatment of toxoplasmosis. 129 Retro-
bulbar injection obtainecl the quickest and highest 
SMX concentration (105 ~tg/mL) in the anterior 
chamber, vitreous, and choroicl/retina. Intravitreal 
clrug concentrations clramatically cleclinecl after 
2.5 hours to 5-10 µg/mL, with maintenance ofhigh 
concentrations at the level of the choroicl/retina 
after 5 hours, enclpoint of the stucly. Intramuscular 
injection showecl a parallel, linear increase of SMX 
in the anterior chamber and vitreous, with concen-
trations very much lower than those founcl after 
retrobulbar injections (10-20 µg/mL). The increase 
of concentration in the vitreous was constant for 
5 hours. Concentration after 1 hour at the choroicl/ 
retina reachecl 40 ~tg/mL, where it oscillatecl for the 
following 4 hours. In rabbits, at least, SMX given 
systemically reaches concentrations in the choroicls/ 
retina above MIC for N. asteroides. Concentrations of 
SMX in the vitreous are probably too low to be 
effective on N. asteroides. Retrobulbar TM-SMX 
injections might be beneficial as a loacling dose 
when starting systemic therapy for EON, but is 
experimen tal. 
Riecler111 found that the concentration of TM in 
the aqueous humor was 60-87% and that of SMX 
20-26% of plasma concentration. Calculated half-
life of the drugs in aqueous humor was 9.7 hours 
for TM (65% of half-life of plasma) and 20.5 hours 
for SMX (190% of half-life of plasma). ln the 
plasma, 66% of SMX and 45% of TM are bouncl to 
proteins and are thus renderecl inactive. SMX 
enterecl less rapiclly in the aqueous humor and 
was there twice as long as in plasma, whereas TM 
entered more quickly into the anterior chamber, 
but was eliminated about one-thircl more quickly 
than in plasma. Intraocular protein binding is 
clependent on intraocular inflammation and is 
unpreclictable. 
In the cases reviewed here, 22% of patients with 
EON responcled to TM-SMX alone, and 16% in 
combination with other antibiotics. Thirteen per-
cent (13%) of patients dicl not respond to systemic 
TM-SMX. Of those with effective systemic treatment, 
five eyes with vitreal sequestration treated by 
sulfadiazine, one by sulfisoxazole, and three with 
TM-SMX dicl not heal. 
ESCHLE-MENICONI ET AL 
Amikacin, an aminoglycoside, has good in vitro 
susceptibility testing results for most strains of 
Nocardia spp. and is bactericiclal. Amikacin has 
a relative high oto-, neuro-, and nephrotoxicity, 
which is cumulative; therapy is usually limited to 
a maximum of 2 weeks. Its penetration into CSF 
is poor.82 Intrathecal irtjection are sometimes 
necessary. 82 
MIC ranges of amikacin are low, 0.25-4 ~tg/mL. 
Intracameral39 concentrations after a single infusion 
of amikacin 7 .5 mg/kg (half dosage for 24 hours) 30 
minutes prior to sampling, topical (15 mg/mL four 
times every 15 minutes prior to surgery) and 
subconjunctival (100 mg) were non-cletectable after 
intravenous, very low after topical, and very variable 
after subconjunctival injection in 15 patients for 
each route of administration unclergoing cataract 
surgery. 
Kasbeer et al65 studiecl in 1975 the penetration 
of intramuscular, topical, and subconjunctival 
amikacin in the rabbit eye65 with normal phakic, 
postoperative aphakic, and aphakic eyes with 
Pseudomonas endophthalmitis. 
After a single intramuscular injection of 15 mg/kg 
amikacin (entire human close for 24 hours) in 
rabbits by Kasbeer et al, concentrations in the 
humor aqueous rangecl from 0.2-2.1 µg/mL in the 
phakic and 1.7-5.1 ~tg/mL in the aphakic eye 3 to 6 
hours after iajection. In the posterior vitreous 
concentrations were lower with 0.1-0.5 µg/mL in 
the phakic and 0.1-0.9 µg/mL in the aphakic eye. In 
another study80 wit:h rabbits, maximal intravitreal 
concentrations of amikacin after intravenous in-
fusion of amikacin 6 mg/kg twice daily, lensectomy 
and vitrectomy wit:h inflammation inducecl by in-
jection of heat-killed Staphylococcus aureus reached 
8.5 (±3.2) ~tg/mL. 
Kasbeer et al appliecl eye drops every 5 minutes 
(10 mg/mL) for 3 hours applying a total of 25 mg. 
Amikacin ranged in the aqueous humor between 0.7 
and 3 µg/mL in the phakic and 0.4--3.2 µg/mL in 
the aphakic eye. There was 0.1-1.0 µg/mL in the 
posterior vitreous of phakic and aphakic eyes. 
Kasbeer et al injected subconjunctival amikacin 
once at 10 mg. Concentrations in the aqueous were 
between 0.7 and 7.5 ~tg/mL in the phakic and 1.3-
10 ~tg/mL in the aphakic eye. In the posterior 
vitreous drug concentration ranged from 0.1-2.5 
~tg/mL in the phakic and 0.1-1.5 ~tg/mL in the 
aphakic eye. Subconjunctival injection of 25 mg 
amikacin by Erkin et al41 resultecl in a mean 
concentration of 9.32 (±2.61) ~tg/mL in the 
aqueous. 
Combining all three routes by Kasbeer et al, in all 
compartments the concentrations were consicler-
able higher: ln the aqueous humor up to 19 ~tg/mL 
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in the phakic and 30 µg/mL in the aphakic eye. 
Concentrations between 0.6 and 4.7 ~Lg/mL and 
0.9-8.3 µg/mL were reached in the posterior 
vitreous of phakic and aphakic non-infected eye, 
respectively, and 0.7-4.0 µg/mL in the infected 
aphakic eye. 
Combination therapy was used with success by 
Tan in a severely inflamed eye of a comatose 
patient. 128 The patient was treated systemically first 
by high-dose TM-SMX, later converted to sulfadia-
zine because of resistance, ceftriaxone, and amika-
cin and weekly subconjunctival amikacin injections, 
topical cefuroxime and gentamycin on a hourly 
basis with tapering to four times daily after 2 weeks. 
Combining systemic, regional, and topical amikacin 
seems of value at least as adjunctive therapy in eyes 
to prevent vitreal sequestration of Nocardia. With 
vitreal invasion, PPV or intravitreal amikacin in-
jections, discussed subsequently, are excellent 
choices. 
Ceftriaxone, a third-generation cephalosporin for 
parenteral use, is only an option for N. asteroides. It is 
bactericidal and has good CSF penetration. Bacte-
riostatic antibiotics (sulfonamides) may interfere 
with the bactericidal effect of ceftriaxone. There is 
physical incompatibility with aminoglycoside, so that 
infusions must be given separately, but there is 
synergism with aminogylcosides. MIC for N. aster-
oides sensu stricto are 2 and 8 µg/mL, for MIC50 and 
MIC90,82 respectively. lntravitreal concentrations in 
patients undergoing surgery for retinal detachments 
and other issues, were 5.9 (±5.5) µg/mL measured 
with high performance liquid chromatography 
(HPLC) and 11.5 (±9) µg/mL by bioassay mea-
sured after 48 hours 2g twice daily intramuscular 
administration. Sorne patients were already vitrec-
tomized, one aphakic patient had the highest 
intravitreal concentration (28 ~Lg/mL bioassay). 122 
Ciprofloxacin, a fluoroquinolone that is bacteri-
cidal, is only to be considerecl for infections with 
N. farcinica. The MIC of N. farcinica ranges between 
0.25 and 8 ~Lg/mL. 82 Thirty-two percent (32%) ofN. 
farcinica isolates are resistant (100% N. nova and 
62% of N. asteroides). Isolates with MIC 90 > 4 µg/ 
mL are consiclerecl resistant. 82 Maximal serum 
concentration after 400 mg IV infusion was 3.9 
mg/L. There is little binding to protein (20-30%) 
with rapicl diffusion into the extracellular space with 
accumulation in different tissues. Only 6-10% of 
maximal serum concentration passes in the CSF. 
Dosage has to be aclaptecl in the elclerly and in 
patients with reduced renal clearance. A single close 
of 750 mg ciprofloxacin resulted in vitreal concen-
tration of 0.19 ~lg/ mL. 66 Two doses yielded mean 
concentrations of 0.51-0.56 µg/mL, 66•75 more or 
less equal to a single administration of 1000 mg with 
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0.64 ~Lg/mL. 22 Subretinal fluid analysis demon-
stratecl 0.74 µg/mL ciprofloxacin after oral, and 
1.05 ~Lg/mL after combined oral and intensive 
topical, application, all analyzed by HPLC. One 
study92 combined their own data of intraocular 
ciprofloxacin concentrations and used pharmaco-
logical models to predict half-lives. The authors 
estimatecl a vitreous half-life of 5.3 hours. With 
dosages of ciprofloxacin 750 mg every 6 hours, they 
found vitreous concentrations of 1.0 ~Lg/mL 
(±0.45), with about 15% of patient still having 
concentration below 0.5 ~Lg/mL. In a rabbit eye 
model with Staphylococcus-inducecl inflammation, the 
. . 98 !' l . l . mvest1gators LOUnc a mean vitrea concentrat10n 
of 1.98 µg/mL with 40 mg/kg ciprofloxacin 
administration (double dosage) in two doses. 
Nemonoxacin-a novel non-fluorinatecl quino-
lone-hacl MIC ranges of0.03-8 µg/mL with MIC90 
at 2 µg/mL on Nocardia spp. (19 isolates including 
three N. farcinica and other unusual species). To our 
knowledge, there are no ocular studies with this 
antibiotic published. 
Imipenem 1 is a beta-lactam with very broad 
spectrum even on bacteria resistant to other beta-
lactams. Imipenem showed the best activity against 51 
isolates among the carbapenems, with meropenem 
being fourfold less active and ertapenem being 16-
fold less active than imipenem,23 whereas in another 
study imipenem, doripenem, and meropenem were 
comparable. 73 It is bactericiclal by inhibition of cell 
wall synthesis of Gram-positive, Gram-negative, an-
aerobe, and aerobe microorganisms. However, its 
penetration in CSF is around 1-20% of serum levels. 
MIC9082 for N. asteroides sensu stricto and N. farcinica 
are around 32 µg/ mL with a range < 0.5 to > 32 µg/ 
mL. Its ocular penetration has been studied after 
single dosage of 1 g intravenously 2-4 hours before 
vitrectomy: 2 µg/mL 8 to 2.5 ~Lg/mL 2 were measured 
by microbiologie clisk agar technique in eyes of 
patients with diabetic retinopathy and retinal de-
tachment with proliferative vitreoretinopathy. One of 
Axelrod's patients had endophthalmitis causecl by 
Staphylococcus epidermidis after cataract extraction. 8 
She receivecl therapy for 4 clays prior to surgery. The 
vitreal concentration was much higher than a single 
close administration at 12. 7 4 µg/ mL. Amikacin and 
imipenem both have unreliable CSF penetration; 
howeve1~ they are synergistic with TM-SMX.82 
Linezolicl, the first oxazolidinone approved in the 
JJnitecl States in 2000 by the Food and Drug 
Administration for < 28-clay treatments of infections 
with resistant germs such as methicillin-resistant 
Staphylococcus, seems a logical option for the 
treatment of nocarcliosis because of its excellent 
in vitro qualities with inhibition of growth of most 
Nocardia spp. with low MIC ranges (0.12-1 µg/mL; 23 
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:S0.25-8 µg/mL; 18 0.5-16 µg/mL 73). Its activity is 
clirected against the 50S ribosomal subunit, specif-
ically to the 23S component, and inhibits initiation 
of protein synthesis. 135 The site of binding is close to 
that of chloramphenicol. Aqueous humor concen-
trations in the non-inflamecl human eye after 
a single oral dose of 600 mg linezolicl was 3.4 
(±1.9) µg/mL measured one hour after inges-
tion.107 Concentrations raisecl to 3.9 (±1.1) µg/ 
mL after two hours, to reach maximum concentra-
tions between two and four hours after intake at 6.8 
(±1.2) ~Lg/mL, to clecline to 3.9 (±1.6) µg/mL after 
4 to 8 hotus. 107 Comparable concentrations were 
reachecl after ingestion of two oral doses of 600 mg 
at 12-hour interval with 6.6 (±2.7) ~Lg/mL samplecl 
18 hours after the first close48 and after single 
intravenous infusion of 600 mg linezolid 5.17 
(±0.95) µg/mL retrievecl 2-4.5 hours after the 
end of the infusion. 134 Vitreal concentrations after 
a single oral dose of 600 mg linezolicl were 1.25 ~Lg/ 
mL measurecl 2-3.5 hours after ingestion.25 Fiscella 
et al48 found 2.34 (±1.4) µg/mL after a mean time 
of 3.5 hours, in the same conditions; and higher 
concentrations after two oral closes of 600 mg 12 
hours apart, taken 18 hours after the first close with 
5.75 (±2.7) ~Lg/mL. Horcajacla et al56 prolonged the 
interval of sample taking to 24 hours and founcl 4.5 
(±0.8) ~Lg/mL, pointing to an accumulation in the 
vitreous. They also measured intravitreal concentra-
tions after intravenous infusion of 600 mg linezolid 
1, 2, 4, 8, and 12 hours after infusion, where 1.0 
(±0.06) µg/mL, 2.2 (±2.0) ~Lg/mL, 3.4 (±1.1) ~tg/ 
mL, 3.7 (±1.4) µg/mL, and 2.4 (±0.4) ~Lg/mL were 
found, respectively. (All measurements were clone 
by HPLC). Linezolid was recently usecl in combina-
tion therapy in a patient with EON 136 (published 
after this review's inclusion period) with a history of 
systemic lupus erythematosus with repeated kiclney 
transplantation on oral prednisone, cyclosporin, 
and mycophenolate mofetile. The subretinal abscess 
was stable under TM-SMX (2 x 960 mg/ day) and 
linezolid (2 x 600 mg/ clay), la ter linezolid alone 
4 x 600 mg (TM-SMX interrupted for anemia and 
thrombocytopenia). Brain lesions indeecl pro-
gressed and warranted an intensification of therapy 
with ampicillin, sulbactam, amikacin, imipenem, 
and cilastin. "Two years after treatment, the ocular 
lesion remains stable and inactive [page 381]. "136 
Linezolicl in its oral form has high bioavailability 
and is comparably well toleratecl for 2-week courses. 
However, with prolonged regimens ( > 28 days to 3-
4 months) linezolicl may leacl to reversible myelo-
suppression ( 45 % ) that progresses 2 weeks beyoncl 
intake. By a probable action on mammalian 
mitochondria, linezolid is neurotoxic in 18% of 
cases leading to irreversible peripheral neuropathy. 
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Bilateral, symmetric, painless optic nemitis, mostly 
reversible, may occur115 on prolongecl treatments 
(120-1505 days; median duration, 280 days). De-
creased visual acuities, sluggish reactive pupils 
without a relative afferent pupillary clefect, optic 
dise eclema, pallor or normal appearance, caeco-
cen tral and/ or arcuate scotomata with impaired 
color vision, extinguished visual potential using the 
20/50 check size, and increasecl retinal nerve fiber 
layer around the optic disk characterize this optic 
l 50 84 B f. . 'cl fr neuropat 1y. ' ecause o lts senous s1 e e Lects on 
long-term therapy,61 linezolid was relegated to 
salvage therapy in a recent review questioning its 
utility in the treatment of nocardiosis. 
A new antibiotic, tigecycline (a glycylcycline, 
a derivate from minocycline, blocking 30S ribo-
some) was founcl to have MIC ranges of :S0.06 to 
4 µg/mL for N. cyriacigemgica in one study.23 It was 
active against imipenem-resistant and TM-SMX-
resistant isolates. A study from Taiwan found slightly 
higher MIC ranges (0.12-8 ~Lg/mL;73 MIC90 at 
4 ~Lg/mL) for N. asteroides. To our knowledge, there 
have been no ocular studies for tigecycline to date. 
In conclusion, depending on clisease progress, 
species, specific resistance pattern, and operative 
state and inflammation of the eye, the response to 
systemic therapy will be variable. 
J. ADJUNCTIVE INTRAVITREAL ANTIBIOTICS 
Intravitreal 400 ~Lg amikacin injections were used 
as adjuncts to systemic treatment in one patient with 
EON101 when the ocular lesions enlargecl while 
brain abscesses regressed. In another patient, 100 
Nocardia was found in the necrotic mass of an 
enucleatecl eye after repeated intravitreal amikacin 
injection. Viability was not tested. 
Arguments in favor of intravitreal amikacin in-
jections are that the MIC is very low (N. asteroides 
comj1lexes, 0.25-4 ~Lg/mL), the MBC is close to 
MIC,85 there are so far no resistant isolates for these 
species,82 and intravitreal amikacin is already widely 
used in clinical practice. Intravitreal amikacin risks 
inducing macular ischemia. A 400-~Lg htjection of 
amikacin gives a theoretical intravitreal concentra-
tion of 100 ~tg/mL that is 25 times greater than the 
MIC90 for amikacin. Clearance of amikacin occurs 
by the anterior route, and inflammation enhances it 
clearance. Different clearance rates have been 
found for variable states of eyes in the rabbit80·85 
(~10rmal, phakic, and aphakic with inflammation, 
etc.). Maurice85 estima te cl that the half-life of a drug 
in a human eye is 1.7 times that of a rabbit. Four to 
five half-lives will bring the initial intravitreal 
concentrations of about 100 ~tg/mL clown to 3-6 
~Lg/mL, still above the MIC range of N. asteroides 
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complex. Four to five half-lives corresponds to 
between 2 and 9 days, depending on the opera-
tive/inflamed state of the eye, calculated in Table 7. 
In regards to toxicity, a single dose of 1500 ~tg 
amikacin produced retinal toxicity in the rab bit eye, 32 
corresponding theoretically to a concentration of 
around 1000 µg/mL (rabbit vitreous, l.4-l.7mL) 
that is 10 times the concentration found in humans 
(400 ~tg in 4 mL). Toxicity may be reached with 
smaller, repeated injections of 400 µg, as shown after 
three injections given at 48-hour intervals in the 
rabbit eye. With a highervolume of distribution in the 
human eye and prolonged intervals between in-
jections, toxicity may be lower than in the rabbit 
eye, but remains uncertain. 
In rabbit eyes, intravit:real TM-SMX (1600 ~tg/0.1 
mL) was found to be nontoxic 2 weeks after its 
administration as shown by histology and electroretino-
gram (ERG) .47 With this dose, a theoretical concentra-
tion of 373 mg/L TM and 1865 mg/L SMX would be 
achieved in the human eye, assuming that the vitreal 
volume is about 4.2 mL. This exceeds the MIC of N. 
asteroides by far (TM, < 2 mg/L; SMX, 38 mg/L). 
Howeve1~ TM-SMX is bacteriostatic and commercially 
available TM-SMX is in a fixed ratio of 1:5. 
ln rabbits, intravitreal 2-mg ceftriaxone injection 
in normal eyes resulted in 445 ~tg/mL concentration 
8 hours and 17.6 ~tg/mL (±1.4) 72 hours after 
· · · 
124 Tl · 1 l . 1 tnject10n. 11s corresponc s to a t 1eoret1ca con-
centration in human eye of 159 ~tg/mL and 6.28 
µg/mL (rabbit vitreal volume:human, 1:2.885 ; 
MIC90 N. asteroides senm stricto 8 µg/mL, N. nova 
16 ~tg/mL). In rabbits, dosages >7.5 mg altered 
ERG transiently for 1 week, and dosages > 20 mg 
affected retinal architecture. In monkeys, the same 
dose of 2-mg ceftriaxone resulted in intravitreal 
concentrations of 609 µg/mL at 0 hours, 434 ~tg/ 
mL at 1 day, and 19 ~tg/mL at 100 hours,10 which are 
higher than the calculated human drug concentra-
tions. There was no toxicity noted by ERG or 
histology. 
In rabbits, intravitreal injection of 0.98 mg 
imipenem (=2-mg tienam in 0.1 mL) was not taxie 
as shown by ERG, visual evoked potential, and 
histology at repeated exams for 6 weeks. The 
authors estimated an intravitreal concentration of 
0.65 mg/mL, which would correspond in humans to 
230 ~tg/mL,-seven times greater than MIC90 for N. 
astemides and N. Jarcinica.77 
K. ROLE OF SURGERY 
The raie of surgery is illustrated in Figs. 6A 
(undiagnosed patient) and 6B (diagnosed and 
systemically treated patient). In half of ail patients 
the diagnosis of disseminated infection by Nocardia 
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was already established when eyes were involved. As 
discussed earlier, the response of infections foci 
elsewhere in the body to systemic antibiotics is not 
an indicator of their ocular efficacy. Multiple small 
choroidal lesions are likely to heal with systemic 
treatment alone. Their increase in size and conflu-
ence, however, indicates progression. A break 
through the retinal pigment epithelium, best 
detected by FA or OCT, should prompt injection 
ofintravitreal antibiotics or surgical management, as 
intravitreal sequestration of Nocardia is unlikely to 
heal by systemic treatment alone. Vitrectomy not 
only decreases the bacterial load, but also enhances 
antibiotic penetration. In our patient, where the 
posterior pole was spared, removal of infected retina 
and subretinal abscess by a retinectomy and silicone 
oil tamponade resulted in an excellent visual and 
anatomical outcome. The importance of a relatively 
aggressive surgical approach when dealing with 
endogenous endophthalmitis and a subretinal ab-
scess has also been emphasized by Harris et al53 and 
Yoon et al 147 in Klebsiella pnewmoniae subretinal 
abscesses-both reporting encouraging postopera-
tive results while dealing with a quick-cycling 
microbe with fulminant disease. ln summary, sur-
gery in EON may be warranted in the absence of 
a therapeutic response to systemic antibiotics, and 
in the presence of bacterial sequestration in the 
vitreous. 
L. PROPOSED MANAGEMENT OF EON 
Our study and other reports emphasize that the 
most important initial step is the suspicion of 
nocardiosis based on the patient's risk factors and 
clinical picture. Figure 6A illustrates the manage-
ment of an undiagnosed patient. A physical exam-
ination should be complemented with a lung CT 
scan (except with history of trauma or surgery) and 
a brain MRI, even in the absence of clinical 
symptoms. Other investigations are undertaken 
based upon the clinical picture. Tissue biopsies are 
the initial steps to identify the causative agent and 
ensure successful treatment: extraocular where 
available or transvitreal subretinal fine-needle bi-
opsy in small or macular lesions with intact outer 
ocular barrier, vitrectomy with disrupted outer 
ocular barrier combined with subretinal biopsy in 
macular lesion, and/ or retinectomy and silicone oil 
tamponade in peripheral lesions. Direct stains, 
cultures incubated for at least 2-4 weeks, and PCR 
studies enhance diagnosis. 
Choice and dosage of systemic antibiotics should 
be made in collaboration with the infectious disease 
specialist. Systemic steroids and chemotherapeutic 
agents decreasing cellular immunity should be 
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reduced as much as possible. Close ophthalmic 
follow-up with repeated FA and/ or OCT is 
advisable. 
Figure 6B illustrates the management after di-
agnosis to evaluate the probability of success of 
conservative treatment alone to treat the eye lesions. 
Intravitreal antibiotics or vitreoretinal surgery is 
indicated when the vitreous is invaded. Prolonged 
follow-up is important for the early detection of 
treatable complications such as cataract, glaucoma, 
retinal detachment, retinal neovascularization, and 
choroidal neovascular membranes. 
VI. Conclusion 
Half of the patients presented first with ocular 
symptoms. Insidious painless loss of vision caused by 
chorioretinal infiltrates or a mass lesion with over-
lying hemorrhages in the macular region with 
a relative mild inflammatory reaction is typical for 
EON. Nocardia either progresses inwards with vitreal 
sequestration or outwards causing perforation. 
Signs of severity that exteriorization is imminent 
are severe ocular pain with either proptosis or 
a hypopyon-or with both. 
A biopsy for adequate microbiology is crucial, 
either from an easily accessible extraocular site or 
from the eye. Transvitreal subretinal fine-needle 
biopsy and PPV with subretinal biopsy have the 
greatest chance to deliver a significant specimen. 
Systemic antibiotics and tapering steroicls are the 
pillars of treatment completed by regional antibi-
otics and surgery. 
VII. Method of Literature Search 
A literature search of case reports of endogenous 
ocular Nocardia was conducted using OVID Medline 
( 1950-2007), EMBASE by meshing keywords Nocar-
dia/ nocardiosis and eye, omlm; endogenous, endophthal-
mitis, subretinal abscess, uveitis. Additional manual 
searches were conducted by using Index Medicus 
(1888-1917), Quarterly Cumulative Index Medicus 
(1917-1950), Excerpta Medica (1947-1966), Oph-
thalmic Lite rature (194 7-1966), Zentralblatt für die 
Gesamte Ophthalmologie und ihre Grenzgebiete 
(1914-1966), and Centralblatt für praktische Au-
genheilkunde (1888-1919) searching for Nocardia, 
Streptothrix, Cladothrix, Proactinomyces (previous terms 
for Nocardia). Exogenous cases of ocular nocardiosis 
such as after ocular trauma or ocular surgery were 
excluded. When EON was present as shown by the 
clinical picture/ microbiology of eye and/ or other 
organs, the case report was includecl, irrespective 
of the language of publication. Two patients' 
ESCHLEMENICONI ET AL 
hl.stor1'e 9,15,52,70 cl . b cl' s were reporte tw1ce y ifferent 
groups (ophthalmologists and internists): The data 
from the correlating field were retained when not 
homogenously reported (data for systemic history 
from the internist group, data for the ocular history 
from the the ophthalmologist group), with excep-
tion when something was not statecl by one group. 
Case reports span the time periocl from 1967 
to 2007. 
VIII. Disclosure 
The authors reportecl no proprietary or commer-
ical interest in any procluct mentionecl or concept 
cliscussed in this article. This article was supportecl 
by Schweizerischer Fonds zur Verhütung und 
Bekampfung der Blindheit, Zürich and the Swiss 
National Science Foundation (MEEM). 
References 
!. Acar JF, Goldstein FW, Kitzis MD, et al. Activity of 
imipenem on aerobic bacteria. J Antimicrob Chemother. 
1983;12(Suppl D):37-45 
2. Adenis JP, Mounier M, Salomon JL, et al. Hu man vitreous 
penetration of imipenem. Eur J Ophthalmol. 1994;4(2): 
115-7 
3. Alfaresi M, Elkosh A. Rapid identification of clinically 
relevant Nocardia species using real-time PCR with SYBR 
Green and melting-curve analysis. J Med Microbiol. 2006; 
55(Pt 12):1711-5 
4. Arduino RC, Johnson PC, Miranda AG. Nocardiosis in 
renal transplant recipients undergoing immunosuppres-
sion with cyclosporine. Clin Infect Dis. 1993;16(4):505-12 
5. Auckenthaler R, Michea-Hamzehpour M, Pechere JC. In 
'~tro activity of newer quinolones against aerobic bacteria. 
J Antimicrob Chemother. 1986;17(Suppl B):29-39 
6. Augsburger JJ. Invasive diagnostic techniques for uveitis 
and simulating conditions. Trans Pa Acad Ophthalmol 
Otolaryngol. 1990;42:964-71 
7. Augsburger.U, ShieldsJA. Fine needle aspiration biopsy of 
solid intraocular tumors: indications, instrumentation and 
techniques. Ophthalmic Surg. 1984; 15 ( 1) :34-40 
8. A.'<elrod JL, Newton JC, Klein RM, et al. Penetration of 
imipenem into human aqueous and vitreous humor. Am J 
Ophthalmol. 1987;104(6):649-53 . 
9. Azap A, Arslan H, Ergin F, et al. Disseminated Nocard.1a 
asteroides and coinfection with Trichophyton mbrum 111 
a renal transplant recipient. Transpl Infect Dis. 2002;4(4): 
223-5 
10. Barza M Lynch E Baum JL. Pharmacokinetics of newer 
cephalo;porins af;er subconjunctival and intravitreal in-
jection in rabbits. Arch Ophthalmol. 1993;111(1):121-5. 
11. Beaman BL, Burnside J, Edwards B, et al. Nocard1.al 
infections in the United States, 1972-1974. J Infect Dis. 
1976;134(3):286-9 . 
12. Berkey P, Bacley GP. Nocardial infection in patients wtth 
neoplastic disease. Rev Infect Dis. 19~9;11 (3):407-12 
13. Bhave AA, Thirunavukkarasu K, Gottlieb DJ, et al. 
inated nocardiosis in a bone marrow transplant rectpt<ruc 
with chronic GVHD. Bane Marrow Transplant. 1\:l\~\J::~~{;t> }: 
519-21 
14. Boiron P, Provost F, Dupont B. u11001:-a.r<Jcy me,tl1<Jc1S 
the microbiological diagnosis of noèax'\:lî.at irv:e1::t1cf1)l!. 
Pasteur Institut ( ed). 
ENDOGENOUS OCULAR NOCARDIOSIS 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
29. 
30. 
31. 
32. 
33. 
34. 
35. 
36. 
diagnosis of nocardia, chapter II, Paris: Pasteur Institut, 
1993, pp 93-101 
Bozbeyoglu S, Yilmaz G, Akova YA, et al. Choroidal abscess 
due to nocardial infection in a renal allograft recipient. 
Retina. 2004;24(1):164-6 
Brown .JM, Pham KN, McNeil MM, Lasker BA. Rapid 
identification of Nocardia farcinica clinical isolates by 
a PCR assay targeting a 314-base-pair species-specific DNA 
fragment.J Clin Microbiol. 2004;42(8):3655-60 
Brown-Elliott BA, BrownJM, Gonville PS, et al. Clinical and 
laboratory features of the Nocardia spp. based on current 
molecular taxonomy. Clin Microbiol Rev. 2006;19(2): 
259-282 
Brown-Elliott BA, Ward SC, Crist CJ, et al. In vitro activities 
of linezolid against multiple Nocardia species. Antimicrob 
Agents Chemothec 2001;45(4):1295-7 
Bullock.JD. Endogenous ocular nocardiosis: a clinical and 
experimental study. Trans Am Ophthalmol Soc. 1983;81: 
451-531 
Burpee JC, Starke WR. Bilateral metastatic intraocular 
nocardiosis. Arch Ophthalmol. 1971;86(6):660-9 
Castro .JG, Espinoza L. Nocardia species infections in 
a large county hospital in Miami: 6 years experience. 
.J Infect. 2007;54(4):358-61 
Cekic 0, Batman C, Yasar U, et al. Human aqueous and 
vitreous humour levels of ciprofloxacin following oral and 
topical administration. Eye. 1999;13(Pt 4):555-8 
Cercenado E, Marin M, Sanchez-Martinez M, et al. In vitro 
activities of tigecycline and eight other antimicrobials against 
different Nocardia species identified by molecular methods. 
Antimicrob Agent~ Chemother. 2007;51(3):1102-4 
Chaudhry NA, Tabandeh H, Davis .J. Successive intraocular 
nocardiosis and cytomegalovims retinitis after cardiac 
transplantation. Arch Ophthalmol. 1998;116(7):960-1 
Giulia TA, Corner GM, Peloquin C, et al. Human vitreous 
distribution of linezolid after a single oral dose. Retina. 
2005;25(5):619-24 
Coll GE, Lewis H. Metastatic choroidal abscess and 
choroidal neovascular membrane associated with Staphy-
lococcus aureus endocarditis in a heroin user. Retina. 1994; 
14(3):256-9 
Gonville PS, Witebsky FG, et al. Nocardia, Rhodococcus, 
Gordonica, Actinomadura, Streptomyces, and other 
aerobic actinomycetes, in Murray PR, Baron E.J,Jorgensen 
.JH (eds), Manual of Clinical Microbiology, ed 9, Vol. 1. 
Oxford, Blackwell Scientific Publishing, ed 9 2007, pp 
515-42 
Gonville PS, Witebsky FG. Organisms designated as 
Nocardia asteroides drug pattern type VI are members of 
the species Nocardia cyriacigeorgica. J Clin Microbiol. 
2007;45 (7):2257-9 
Costen MT, Harrison A, Crick MP. Bilateral reactive 
subretinal abscesses following S. pyogenes septicaemia. 
Eye. 2001;15(Pt 4):561-2 
Couble A, Rodriguez-Nava V, de Montclos MP, et al. Direct 
detection of Nocardia spp. in clinical samples by a rapid 
molecular method . .J Clin Microbiol. 2005;43(4):1921-4 
Daly AS, McGeer A, Lipton .JH. Systemic nocardiosis 
following allogeneic bone marrow transplantation. Transpl 
Infect Dis. 2003;5 ( l): l 0-20 
D'Amico qJ, Caspers-Velu L, Libert J, et al. Comparative 
toxicity of intravitreal aminoglycoside antibiotics. Am J 
Ophthalmol. l 985;100(2):264-75 
Davidson S, Foerster HG. Intraocular nocardial abscess, 
endogenous. Trans Am Acad Ophthalmol Otolaryngol. 
1967;71 (5):847-50 
Davitt B, Gehrs K, Bowers T. Endogenous Nocardia 
endophthalmitis. Retina. 1998;18(1):71-3 
De Silva T, Evans C, Mudhar HS, et al. Isolated endogenous 
endophthalmitis secondary to Nocardia spp in an immu-
nocompetent adult.J Clin Pathol. 2006;59(11):1226 
Detering K, Jenney A, Hall A, et al. Metastatic choroidal 
abscess due to Pseudomonas aeruginosa in patients with 
cystic fibrosis. Clin Infect Dis. 1997;24(3):525-6 
37. 
38. 
39. 
40. 
41. 
42. 
43. 
44. 
45. 
46. 
47. 
48. 
49. 
50. 
51. 
53. 
54. 
55. 
56. 
57. 
58. 
59. 
411 
Dodds EM, Echandi LV, Puente SI, et al. Subretinal abscess 
due to Nocardia farcinica resistant to trimethoprim-
sulfamethoxazole in a patient with systemic lupus eryth-
ematosus. Ocul Immunol Inflamm. 2006;14(4):249-51 
Dominguez DG, Antony SJ. Actinomyces and nocardia 
infections in immunocompromised and nonimmunocom-
promised patients. J Natl Med Assoc. 1999;91 (1):35-9 
Eiferman RA, Stagner JI. Intraocular penetration of 
amikacin. Iris binding and bioavailability. Arch Ophthal-
mol. 1982;100(11):1817-9 
Eppinger H. Ueber eine neue, pathogene Cladothrix und 
eine durch sie hervorgerufene Pseudotuberculosis ( clado-
thrichica). Beitraege zur Pathologischen Anatomie und zur 
Allgemeinen Pathologie. 1890;9:287-328 
Erkin EF, Gunenc U, Oner FH, et al. Penetration of 
amikacin into aqueous humor of rabbits. Ophthalmolog-
ica. 2001;215(4):299-302 
Exmelin L, Malbruny B, Vergnaud M, et al. Molecular 
study of nosocomial nocardiosis outbreak involving heart 
transplant recipients. J Clin Microbiol. 1996;34(4): 
1014-6 
Farina C, Boiron P, Ferrari I, et al. Report of human 
nocardiosis in Italy between 1993 and 1997. Eur J 
Epidemiol. 2001; 17 ( 11): 1019-22 
Farina C, Boiron P, Goglio A, et al. Human nocardiosis in 
northern Italy from 1982 to 1992. Northern Italy Collab-
orative Croup on Nocardiosis. Scand J Infect Dis. 1995; 
27(1):23-7 
Ferry AP, Font RL, Weinberg RS, et al. Nocardial 
endophthalmitis: report of two cases studied histopatho-
logically. Br.J Ophthalmol. 1988;72(1):55-61 
Filice GA. Nocardiosis in persans with human immunode-
ficiency virus infection, transplant recipients, and large, 
geographically defined populations . .J Lab Clin Med. 2005; 
145(3):150-62 
Fiscella R, Peyman GA, Kimura A, et al. Intravitreal toxicity 
of cotrimoxazole. Ophthalmic Surg. 1988;19(1):44-6 
Fiscella RG, Lai WW, Buerk B, et al. Aqueous and vitreous 
penetration of linezolid (Zyvox) after oral administration. 
Ophthalmology. 2004;1 ll (6):1191-5 
Frumkin A. Nocardial infections in Israel: a survey. Isr .J 
Med Sei. 1989;25(6):324-7 
Gallant.JE, Ko AH. Cavitary pulmonary lesions in patients 
infected with human immunodeficiency virus. Clin Infect 
Dis. 1996;22(4):671-82 
Georghiou PR, Blacklock ZM. Infection with Nocardia 
species in Queensland. A review of l 02 clinical isola tes. 
MedJ Aust. 1992;156(10):692-7 
Gregor RJ, Chong CA, Augsburger JJ, et al. Endogenous 
Nocardia asteroides subretinal abscess diagnosed by trans-
vitreal fine-needle aspiration biopsy. Retina. 1989;9(2): 
118-21 
Harris EW, D'Amico D.J, Bhisitkul R, et al. Bacterial 
subretinal abscess: a case report and review of the 
literature. Am .J Ophthalmol. 2000;129(6):778-85 
Heron E, Augustin P, Cervera P, et al. Systemic nocardiosis 
mimicking an ocular relapse of giant cell arteritis. 
Rheumatology (Oxford). 2006;45(5):641-3 
Holak H, Becker R, Holak S. [Long-term follow-up of 
bilateral endogenous Klebsiella endophthalmitis]. Klin 
Monatsbl Augenheilkd. 2003;220(5):357-61 
HorcajadaJP, Atienza R, Sarasa ~[, et al. Pha~macokinetics 
of linezolid in human non-mflamed v1treous after 
systemic administration. J Antimicrob Chemother. 2009; 
63(3):550-2 
Ishibashi Y, vVatanabe R, Hommura S, et al. Endogenous 
Nocardia asteroides endophthalmitis in a patient with 
systemic lupus erythematosus. Br J Ophthalmol. 1990; 
74(7):433-6 
Jain A, Egbert P, McCulley 1J, et al; . Endogenous 
Scedosporium apiospermum endophthalmttts, Arch Oph-
thalmol. 2007;125(9):1286-9 
Jampol LM, Strauch BS, Albert DM .. I11traocular nocardio-
sis. Am] Ophthalmol. 1973;76(4):568-73 
412 
60. 
61. 
62. 
63. 
64. 
6" 
"· 
66. 
67. 
68. 
69. 
70. 
71. 
72. 
73. 
74. 
75. 
76. 
77. 
78. 
79. 
80. 
81. 
82. 
83. 
Surv Ophthalmol 56 (5) September-October 2011 
Javaheri M, Khurana RN, O'Hearn TM, et al. Linezolid-
induced optic neuropathy: a mitochondrial disorder? Br J 
Ophthalmol. 2007;91 (1):111-5 
Jodlowski TZ, Melnychuk I, Corny .J. Linezolid for the 
treatment of Nocardia spp. infections. Ann Pharmacother. 
2007;41 (10):1694--9 
Jolly SS, Brownstein S. Endogeneous Nocardia subretinal 
abscess. Arch Ophthalmol. 1996;114(9):1147-8 
.Jones N, Khoosal M, Louw M, et al. Nocardial infection as 
a complication of HIV in South Africa . .J Infect. 2000;41 (3): 
232-9 
Kageyama A, Yazawa K, Ishikawa .J, et al. Nocardial 
infections in .Japan from 1992 to 2001, including the first 
report of infection by Nocardia transvalensis. Eur .J 
Epidemiol. 2004;19(4):383-9 
Kasbeer RT, Peyman GA, May DR, et al. Penetration of 
amikacin into the aphakic eye. Albrecht Von Graefes Arch 
IGin Exp Ophthalmol. 1975;196(1):85-94 
Keren G, Alhalel A, Bartov E, et al. The intravitreal 
penetration of orally administered ciprofloxacin in hu-
mans. Invest Ophthalmol Vis Sei. 1991;32(8):2388-92 
Kim EK, Lee DH, Lee K, et al. Nocardia keratitis after 
traumatic detachment of a laser in situ keratomileusis flap. 
J Refract Surg. 2000;16(4):467-9 
Kim .J, Minamoto GY, Grieco MH. Nocardial infection as 
a complication of AIDS: report of six cases and review. Rev 
Infect Dis. 1991;13(4):624--9 
Kim .JE, Landon RE, Connor TB .J1; et al. Endogenous 
ocular nocardiosis . .J Aapos. 2004;8(2):194--5 
Knouse MC, Lorber B. Early diagnosis of Nocardia 
asteroides endophthalmitis by retinal biopsy: case report 
and review. Rev Infect Dis. 1990;12(3):393-8 
Korkmaz C, Aydinli A, Ero! N, et al. Widespread nocardio-
sis in two patients with Behcet's disease. Clin Exp 
Rheumatol. 2001;19(4):459-62 
Kursat S, Ok E, Zeytinoglu A, et al. Nocardiosis in renal 
transplant patients. Nephron. 1997;75(3):370-1 
Lai CC, Tan CK, Lin SH, et al. Comparative in vitro 
activities of nemonoxacin, doripenem, tigecycline and 16 
other antimicrobials against Nocardia brasiliensis, Nocar-
dia asteroides and unusual Nocardia species . .J Antimicrob 
Chemother. 2009;64(1):73-8 
Lakosha H, Pavlin C.J, Lipton .J. Subretinal abscess due to 
Nocardia farcinica infection. Retina. 2000;20(3):269-74 
Lesk MR, Ammann H, Mareil G, et al. The penetration of 
oral ciprofloxacin into the aqueous humor, vitreous, and 
subretinal fluid of humans. Am .J Ophthalmol. 1993; 
115(5):623-8 
Lissner GS, O'Grady R, Choromokos E. Endogenous 
intraocular Nocardia asteroides in Hodgkin's disease. Am 
.J Ophthalmol. 1978;86(3):388-94 
Loewenstein A, Zemel E, Lazar M, Perlman I. Drug-
induced retinal toxicity in albino rabbits: the effects of 
imipenem and aztreonam. Invest Ophthalmol Vis Sei. 
1993;34(12) :3466--76 
Mamalis N, Daily M.J, Ross D. Presumed intraocular 
nocardiosis in a cardiac-transplant patient. Ann Ophthal-
mol. 1988;20(7):271-3, 276. 
Mamelak AN, Obana WG, Flaherty.JF, et al. Nocardial brain 
abscess: treatment strategies and factors influencing out-
come. Neurosurgery. 1994;35(4):622-31 
Mandell BA, Meredith TA, Aguilar E, et al. Effects of 
inflammation and surgery on amikacin levels in the 
vitreous cavity. Am .J Ophthalmol. 1993;115(6):770-4 
Matulionyte R, Rohner P, U ckay I, et al. Secular trends of 
nocardia infection over 15 years in a tertiary care hospital.J 
Clin Pathol. 2004;57(8):807-12 
Mc Neil M, Brown.J. Nocardia species (Nocardiosis), in Yu 
V, Weber R, Raoult D (eds), Antimicrobial Therapy and 
Vaccines, ed 2, Vol. 1. New York, Apple Trees Production, 
LLC, ed 2 2002, pp 481-500 
McGuire TW, Bullock .JD, Bullock .JD Jr, et al. Fungal 
endophthalmitis. An experimental study with a review of 
84. 
85. 
86. 
87. 
88. 
89. 
90. 
91. 
92. 
93. 
94. 
95. 
96. 
97. 
98. 
99. 
100. 
101. 
102. 
103. 
104. 
105. 
ESCHLE-MENICONI ET AL 
17 human ocular cases. Arch Ophthalmol. 1991;109(9): 
1289-96 
McKinley SH, Foroozan R. Optic neuropathy associated 
with linezolid treatment. J Neuroophthalmol. 2005;25(1): 
18-21 
Meredith TA, et al. Antibiotics and antifungals, in Zimmer-
man 'IJ, Kooner KS, Sharir M (eds) Textbook of Ocular 
Pharmacology. 1997. Philadelphia, PA, Lippincott-Raven, 
ed 1 1997, pp 63-385 
Messmer EM. Candidiasis, in Foster CS, Vitale AT (eds) 
Diagnosis and Treatment ofUveitis. 2002. Philadelphia, PA, 
W.B.Saunders Company, 2002, pp 364--72 
Meyer SL, Font RL, Shaver RP. Intraocular nocardiosis. 
Report of three cases. Arch Ophthalmol. 1970;83 (5) :536--41 
Minera MV, Marin M, Cercenado E, et al. Nocardiosis at 
the turn of the centm-y. Medicine (Baltimore). 2009;88(4): 
250-61 
Mishra SK, Sandhu RS, Randhawa HS, et al. Effect of 
cortisone administration on experimental nocardiosis. 
Infect Immun. 1973;7(2): 123-9 
Moiton MP, Robert D, Bebear CM, et al. [Clinical, 
microbiological, and therapeutic aspects of Nocardia sp. 
infections in the Bordeaux hospital from 1993 to 2003]. 
Med Mal Infect. 2006;36(5):264--9 
Mok CC, Yuen KY, Lau CS. Nocardiosis in systemic 
lupus erythematosus. Sernin Arthritis Rheum. 1997; 
26( 4):675-83 
Morlet N, Graham GG, Catus B, et al. Pharmacokinetics of 
ciprofloxacin in the human eye: a clinical study and 
population pharmacokinetic analysis. Antimicrob Agent~ 
Chemother. 2000;44(6): 1674--9 
Moshfeghi DM, Sears JE, Lewis H. Submacular surgery for 
choroidal neovascularization following nocardial endoph-
thalmitis. Retina. 2004;24(1):161-4 
Ness T, Pelz K, Hansen LL. Endogenous endophthalmitis: 
microorganisms, disposition and prognosis. Acta Ophthal-
mol Scand. 2007;85 (8) :852-6 
Ng EW, Zimme1~Galler IE, Green WR. Endogenous 
Nocardia asteroides endophthalmitis. Arch Ophthalmol. 
2002;120(2) :210-3 
Niehues R, Schluter S, Kramer A, et al. [Systemic Nocardia 
asteroides infection with endocardial involvement in 
a patient undergoing immunosuppressive therapy]. Dtsch 
Med Wochenschr. 1996; 121 ( 45): 1390-5 
Nocard ME. Note sur la maladie des boeufs de la 
Guadeloupe connue sous le nom de farcin. Ann Inst Past. 
1888;2:293-302 
Ozturk F, Kortunay S, Kurt E, et al. Effects of trauma and 
infection on ciprofloxacin levels in the vitreous cavity. 
Retina. 1999;19(2):127-30 
Panijayanond P, Olsson CA, Spivack ML, et al. Intraocular 
nocardiosis in a renal transplant patient. Arch Surg. 1972; 
104(6):845-7 
Pelayes DE, Colombero D, Gioino .JM, et al. [Endogenous 
Nocardia asteroides endophthalmitis in a patient with 
systemic lupus e1-ythematosus]. Medicina (B Aires). 2004; 
64(2):146-8 
Phillips WB, Shields CL, Shields .JA, et al. Nocardia 
choroidal abscess. Br J Ophthalmol. 1992;76(11):694--6 
Pintado V, Gomez-Mampaso E, Cobo J, et al. Nocardial 
infection in patients infected with the human immunode-
ficiency virus. Clin Microbiol Infect. 2003;9(7):716--20 . 
Pintado V, Gomez-Mampaso E, Fortun J, et al. Infect10n 
with Nocardia spedes: clinical spectrum of disease and 
species distribution in Madrid, Spain, 1978-2001. Infec-
tion. 2002;30(6):338-40 
Pohjanpelto PE, Sarmela T.J, Raines ~· Penetration of 
trimethoprim and sulphamethoxazole mto the aqueous 
humour. Br J Ophthalinol. 1974;58{6):606--8 
Poonwan N, Mekha N, Yazawa K, et al. Characterization of 
clinical isolates of pathogenic Nocardia strains and related 
actînomycetes in Thailand from 1996 to 2003. Mycopatho-
logia. 2005;159(3):361-8 
ENDOGENOUS OCULAR NOCARDIOSIS 
106. 
107. 
108. 
109. 
110. 
111. 
112. 
113. 
114. 
115. 
116. 
117. 
118. 
119. 
120. 
121. 
122. 
123. 
124. 
125. 
126. 
Price NC, Frith PA, Awd1y PN. Intraocular nocardiosis: 
a further case and review. Int Ophthalmol. 1989;13(3): 
177-180 
P1ydal JI, .Jenkins DR, Lovering A, et al. The pharmacoki-
netics of linezolid in the non-inflamed human eye. Br J 
Ophthalmol. 2005;89(11):1418-9 · 
Queipo-Zaragoza JA, Broseta-Rico E, Alapont-Alacreu JM, 
et al. Nocardial infection in immunosuppressed kidney 
transplant recipients. Scand J Uro! Nephrol. 2004;38(2): 
168-73 
Rafiei N, Tabandeh H, Bhatti MT, et al. Retinal fibrovas-
cular proliferation associated with Nocardia subretinal 
abscess. Eurj Ophthalmol. 2006;16(4):641-3 
Rao NA, Hidayat AA. Endogenous mycotic endophthalmi-
tis: variations in clinicat and histopathologic changes in 
candidiasis compared with aspergillosis. Amj Ophthalmol. 
2001; 132 (2) :244-51 
Rieder J, Ellerhorst B, Schwartz DE. [Penetration of 
sulfamethoxazole and trimethoprim into the anterior 
chamber in humans (author's transi)]. Albrecht Von 
Graefes Arch Klin Exp Ophthalmol. 1974;190(1):51-61 
Rimpel NR, Cunningham ET Jr, Howes EL.Ji; et al. Viridans 
group Streptococcus subretinal abscess. Br J Ophthalmol. 
1999;83(3):373-4 
Rodriguez-Nava V, Couble A, Devulder G, et al. Use of PCR-
restriction enzyme pattern analysis and sequencing data-
base for hsp65 gene-based identification of Nocardia 
species. J Clin Microbiol. 2006;44(2) :536--46 
Rogers SJ, .Johnson BL. Endogenous Nocardia endoph-
thalmitis: report of a case in a patient treated for 
lymphocytic lymphoma. Ann Ophthalmol. 1977;9(9): 
1123-31 
Rucker JC, Hamilton SR, Bardenstein D, et al. Linezolid-
associated taxie optic neuropathy. Neurology. 2006;66(4): 
595-8 
Sahathevan M, Harvey FA, Forbes G, et al. Epidemiology, 
bacteriology and control of an outbreak of Nocardia 
asteroides infection on a li ver unit. .J Hosp Infect. 1991; 
18(Suppl A):473-80 
Salmon JD, Fowle AS, Bye A. Concentrations of trimetho-
prim and sulphamethoxazole in aqueous humour and 
plasma from regimens of cotrimoxazole in man. J 
Antimicrob Chemother. 1975;1 (2):205-11 
Samson M, Foster CS. Tuberculosis, in Foster CS, Vitale AT 
(ed). Diagnosis and Treatment of Uveitis. Philadelphia, PA, 
W.B. Saunders Company, 2001, pp 264-72 
Saubolle îVIA, Sussland D. Nocardiosis: review of clinical 
and laborat01y experience . .J Clin Microbiol. 2003;41 (10): 
4497-501 
Schaal KP, Lee H.J. Actinomycete infections in humans-
a review. Gene. 1992;115(1-2):201-11 
Schriever S, Mistiy-Burchardi N, Grabein B, et al. [Noca1~ 
dia farcinica: life-threatening chorioiditis under systemic 
immunosuppression]. Klin Monatsbl Augenheilkd. 2002; 
219(3):164-7 
Sharir M, Triester G, Kneer .J, et al. The intravitreal 
penetration of ceftriaxone in man following systemic 
administration. Invest Ophthalmol Vis Sei. 1989;30(10): 
2179-83 
Sher NA, Hill CW, Eifrig DE. Bilateral intraocular 
Nocardia asteroides infection. Arch Ophthalmol. 1977; 
95(8):1415-8 
Shockley RK, .Jay WM, Friberg TR, et al. Intravitreal 
ceftriaxone in a rabbit mode!. Dose- and time-dependent 
taxie effecl5 and pharmacokinetic analysis. Arch Ophthal-
mol. 1984;102(8):1236-8 
Smith SR, Kroll A.J, Lou PL, et al. Endogenous bacterial 
and fungal endophthalmitis. Int Ophthalmol Clin. 2007; 
47(2):173-83 
Sorrell TC, Iredell .JR, DMitchel DH. Higher bacterial 
diseases, Nocardia species, in Mandell GL (ed), Principles 
and Practice of Infectious Diseases, ed 6, Vol. 2. Phila-
delphia, PA, Elsevie1; ed 6 2005, pp 2637-45 
127. 
128. 
129. 
130. 
131. 
132. 
133. 
134. 
135. 
136. 
137. 
138. 
139. 
140. 
141. 
142. 
143. 
144. 
145. 
146. 
147. 
148. 
149. 
413 
Suppiah R, Abraham G, Sekhar U, et al. Nocardial 
endophthalmitis leading to blindness in a renal ti·ans-
plant recipient. Nephrol Dia! Transplant. 1999·14(6)' 
1576-7 ' . 
Tan SY, Tan LH, Teo SM, et al. Disseminated nocardiosis 
with bilateral intraocular involvement in a renal allograft 
patient. Transplant Proc. 2000;32(7):1965-6 
~assignon ~U, Brih~ye M, De Meuter F, et al. [Efficacy of 
t1eatments 111 expenmental toxoplasmosis]. Bull Soc Belge 
Ophtalmol. 1989;230:59-72 
Torres HA, Reddy BT, Raad II, et al. Nocardiosis in cancer 
patients. Medicine (Baltimore). 2002;81(5):388-97 
T5ukamura M. Numerical analysis of the taxonomy of 
Nocardiae and Rhodococci. Microbiol Immunol. 1982; 
26(12):1101-19 
Vagefi MR, Kim ET, Alvarado RG, et al. Bilateral 
endogenous Scedosporium prolificans endophthalmitis 
after Jung transplantation. Am .J Ophthalmol. 2005; 
139(2):370-3 
van BurikJA, Hackman RC, Nadeem SQ, et al. Nocardiosis 
after bone marrow transplantation: a retrospective study. 
Clin Infect Dis. 1997;24(6):1154-60 
Vazquez EG, Mensa J, Lapez Y, et al. Penetration of 
linezolid into the anterior chamber (aqueous humor) of 
the human eye after intravenous administration. Antimi-
crob Agents Chemother. 2004;48(2):670-2 
Vinh DC, Rubinstein E. Linezolid: a review of safety and 
tolerability. J Infect. 2009;59 (Suppl 1) :S59-74 
Vossmerbaeumer U, Spandau UH, Kleinhuber K, et al. 
Arrest of endogenous ocular nocardiosis under linezolid 
therapy. Acta Ophthalmol. 2010;88(3):381-3 
Wallace ~J .Jr, Brown BA, Tsukamura M, et al. Clinical and 
laborato1y features of Nocardia nova . .J Clin Microbiol. 
1991;29(11):2407-11 
Wallace RJ Jr, Steele LC, Sumter G, et al. Antimicrobial 
susceptibility patterns of Nocardia asteroides. Antimicrob 
Agents Chemother. 1988;32(12):1776-9 
Wallace ~J .Jr, Tsukamura M, Brown BA, et al. Cefotaxime-
resistant Nocardia asteroides strains are isolates of the 
controversial species Nocardia farcinica . .J Clin Microbiol. 
1990;28( 12) :2726--32 
Webber SK, Andrews RA, Gillie RF, et al. Subretinal 
Pseuclomonas abscess afler lung transplantation. Br .J 
Ophthalmol. 1995;79(9) :861-6 
Wijesekera NT, Kon OM, Pavesio C. Subretinal Pseuclomo-
nas abscess in a patient with bronchiectasis. Eye. 2004; 
18(2):196, discussion 196--7 
Xiao M, Kong F, Sorrell TC, et al. Identification of 
pathogenic Nocardia species by reverse line blot hybrid-
ization targeting the 16S rDNA and 16S-23S rDNA spacer 
regions . .J Clin Microbiol. 2010;48(2):503-11 
Yao TC, Hung U, Su LH, et al. Endogenous endophthal-
mitis and necrotising pneumonia caused by Klebsiella 
pneumoniae in a child with beta-thalassaemia major. Eur J 
Pediatr. 2001;160(7):449 
Yap EY, Fam HB, Leang KP, et al. Nocatdia choroidal 
abscess in a patient with systemic lupus erythematosus; Aust 
NZ.J Ophthalmol. 1998;26(4):337-8 .· ·. <. 
Yassin AF, Rainey FA, Mendrock U, etal. Nocarcha abscessus. 
sp. nov. Int.J Syst Evol MicrobioL 2000;50(Pt 4~:1~~7~93 " 
Yin x, Liang S, Sun X, ~t ~!. O~ular.11o:c~1.1:th9s1?: trS~.6n 
gene sequencing for spec1es 1clel)t1ticu~~~\9flN:~car~(~ s:gp. 
Am.J Ophthalmol. 2007;144(4}:p'70-l) ; .. ·.•·· .. · • 
Yoon YH, Lee SU, Sohn J-f['. Lt:.(} ~,.. · 
vitrectomy for enclogenous}aebslèlll.t 
thr.lmitls. Retina. 2003;23:3 
Yu E, Laughlin .. .S;. l{assel 
thalmitis and subretlrta! 
features with. pu.t 
Am .J Neurcmtdi.o 
Zaatreh M, Alà~ 
Dissem1 
Med<20 
414 Surv Ophthalmol 56 (5) Septembe1~0ctober 2011 
Other Cited Material 
A. www.dsmz.de/microorganisms/bacterial_nomenclature_ 
info.php?genus= Nocardia&show_all_details= 1). 
The authors offer their thanks to the colleagues at the CHUV 
who managed the patient and to their colleagues at the Jules 
Gonin Eye Clinic: to Sylvie Uffer for the Gram staining and 
pictures in Figure 2, to Marc Curchot for the pictures, to 
ESCHLE-MENICONI ET AL 
Madelaine Badan for bibliography support, and to Alexander 
Moulin for the autopsy. Furthermore, they wish to thank Mahnaz 
Nouri (Boston, MA) for corrections, Peter Keller from the 
microbiology laboratory university hospital, Zürich for discussion 
and corrections, and Martin Eschle for IT support. 
Reprint address: Thomas]. Wolfensberger, MD, PD, MER, Jules 
Gonin Eye Hospital, 15 Av. de France, CH-1000 Lausanne 7, 
Switzerland. e-mail: thomas.wolfensberger@fa2.ch. 
Outline 
I. Introduction 
II. Case report 
III. Ophthalmic case reports 
A. Inclusion criteria 
B. Exclusion criteria 
C. Methods 
IV. Results of literature review of endogenous 
ocular nocardiosis 
A. Systemic features and mortality of nocar-
diosis in patients with EON 
1. Species of Nocardia reported in EON 
2. Age and sex distribution of patients 
3. Predisposing risk factors 
a. Diseases 
b. l'vledications 
4. Systemic involvement in the presence of 
EON 
5. Disease recurrence and mortality of 
patients with EON 
B. Ophthalmic features and ocular morbidity 
of EON 
1. Laterality of eye involvement 
2. Temporal relationship of eye and sys-
temic symptoms 
3. Ocular symptoms 
4. Visual acuity at presentation 
5. Ocular findings 
a. Confunctiva, cornea, sclera, orbit, exterior-
ization/perforation 
b. Anterior chamber; iris 
c. Vitreous 
d. Chorioretinitis, subretinal abscesses 
e. Serous retinal detachment 
6. Fluoresceine and indocyanine green 
angiography of acute and healecl lesions 
7. Optical coherence tomography 
8. Ultrasound findings of acute lesions 
V. 
9. Magnetic resonance imaging 
10. Differential diagnosis evokecl by the 
au th ors 
11. Time to diagnosis and diagnostic 
pro ce dures 
a. Specimens tahen from elsewhere than the eye 
b. Ocular specùnen talœn, successjul versus 
unsuccessful procedures in identifying the 
pathogen 
c. Complications related ta diagnostic octtlar 
procedures 
12. Number of ineffective treatments before 
diagnosis 
13. Efficacy of Trimethoprim-Sulpha-
methoxazole 
14. Responses of eyes exposed to effective 
systemic antibiotic treatment and eyes 
that failed to respond 
15. Systemic recurrences by sequestered No-
cardia in the eye 
16. Evolution of lesions after treatment, 
secondary complications, and their 
treatment 
17. Significance of ocular 
18. Pathology findings rPr,orrPn 
eyes, of eyes with 
that 
ENDOGENOUS OCULAR NOCARDIOSIS 
E. Risk factors, steroids, and immunosuppres-
sives in animal models of EON 
F. Delay in diagnosis, differen tial diagnosis with 
respect to microbes possibly involved 
G. Role of fluorescein angiography in the di-
agnosis and treatment, transvitreal subretinal 
fine-needle biopsyversus pars plana virectomy 
H. Significance of ocular pain, proptosis and 
hypopyon 
1. Appropriate systemic antibiotics 
415 
1. Intraocular drug levels attainable with 
systemic or regional administration of 
antibiotics 
J. Acljunctive intravitreal antibiotics 
K. Role of surgery 
L. Proposed management of EON 
VI. Conclusion 
VII. Method of literature search 
VIII. Disclosure 
